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Abstract 
In 2017, 7.1% of US adults were diagnosed with depression, and 50% of patients 
received medication to treat their depression. Depression can cause severe interruptions in an 
individual’s cognitive functioning and behaviors like sleeping, eating, working, and socializing. 
Unfortunately, approximately 40% of patients do not respond to treatment with monoaminergic 
medications (e.g. Prozac®) and therapeutic effects may be delayed 2-8 weeks. Due to these 
therapeutic shortcomings, faster acting and more efficacious treatments are needed. Recent 
preclinical findings indicate potential for glutamatergic drugs like (R,S)-ketamine and (2R,6R)-
hydroxynorketamine to produce more rapid and longer-acting therapeutic effects. The 
antidepressant effectiveness of (R,S)-ketamine for many patients is undisputed; however, the 
antidepressant efficacy of the ketamine metabolite (2R,6R)-hydroxynorketamine is disputed. 
Despite an incomplete understanding of the mechanism of action, the FDA approved (S)-
ketamine (esketamine; Ketanest®, Spravato®) for treatment-resistant depression in March 2019. 
Excitement for a better treatment, however, is lessened by reports indicating that some patients 
may experience severe side effects like reduced cognitive functioning a day or more after (S)-
ketamine treatment. In sum, some glutamatergic drugs like (R,S)-ketamine are effective in 
treating depression, but potential side-effects and abuse liability may limit their clinical use. This 
provides a strong impetus to further examine and compare the antidepressant efficacy and side-
effects of (R,S)-ketamine, the ketamine isomers (R)-ketamine, (S)-ketamine, and the ketamine 
metabolite (2R,6R)-hydroxynorketamine. The current study measured the effects of (R,S)-
ketamine, (R)-ketamine, (S)-ketamine, and (2R,6R)-hydroxynorketamine on C57bl/6 mice in 
three preclinical behavioral assays; differential-reinforcement-of-low-rate responding (DRL), 
drug discrimination, and spontaneous alternation in a Y-maze. These assays provide measures of 
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antidepressant-like effects, discriminative stimulus effects, and cognitive effects of drugs, 
respectively. Results indicated that (R,S)-ketamine, (S)-ketamine, and (2R,6R)-
hydroxynorketamine produced significant antidepressant-like effects in the DRL task. No 
significant effect was found with (R)-ketamine in the DRL task. The lack of effect in the DRL 
task may be due to the slower metabolism of (R)-ketamine compared to (S)-ketamine and the 10-
minute pretreatment time used in the present study. In the drug discrimination experiment, both 
isomers substituted for (R,S)-ketamine; the effective dose of (S)-ketamine was lower than (R)-
ketamine and this indicates greater potency in this experiment. (2R,6R)-Hydroxynorketamine did 
not substitute for (R,S)-ketamine at the tested doses. In the Y-maze experiment, (R,S)-ketamine 
and (S)-ketamine reduced spontaneous alternation 24-hours after injection. No effect on 
spontaneous alternation was observed with (R)-ketamine and (2R,6R)-hydroxynorketamine at the 
tested doses. The results from the Y-maze experiment indicate that (R)-ketamine and (2R,6R)-
hydroxynorketamine may have less effect on cognition than (R,S)-ketamine and (S)-ketamine. 
The present study reports novel findings regarding the antidepressant-like effects, subjective 
effects, and cognitive effects of (R,S)-ketamine, its isomers, and the metabolite (2R,6R)-
hydroxynorketamine. The results of the present study and many other preclinical studies suggest 
that clinical research is warranted for the (R)-ketamine (arketamine) isomer and the ketamine 
metabolite, (2R,6R)-hydroxynorketamine.  
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Effects of (R,S)-ketamine and (2R,6R)-hydroxynorketamine: a preclinical study 
 Major depressive disorder is the most common mental health disorder and a major cause 
of disability-adjusted life years lost worldwide (Murray & Lopez, 1996; Kessler, 2012; World 
Health Organization [WHO], 2019). In 2012, the U.S. lifetime prevalence rate for depression 
was over 16% (Kessler et al., 2012). During 2013-2016, 8.1% of persons in the U.S. aged 20 and 
over had depression in any given two-week period (Brody, 2018). In 2005, treatment and loss of 
productivity due to depression was estimated to have cost the US $173.2 billion; which increased 
to $210.5 billion in 2010 (Greenberg, Fournier, Sisitsky, Pike, & Kessler, 2015). About 80% of 
adults with depression in the U.S., report some difficulty with work and social activities because 
of their depression (Brody, 2018). Depression is associated with persistent symptoms that extend 
well beyond momentary sadness (National Institute of Mental Health [NIMH], 2016). 
Depression can cause severe interruptions in an individual’s thoughts, by affecting emotions and 
cognitive functioning, and behaviors like sleeping, eating, working, and socializing (NIMH, 
2013). Symptoms may range from mild to severe and to be diagnosable as defined by the 
Diagnostic and Statistical Manual (DSM-5) of the American Psychiatric Association, symptoms 
must persist for at least two weeks (see Table 1; NIMH, 2013; Uher, Payne, Pavlova, & Perlis, 
2014; American Psychiatric Association, 2017). Fortunately, some patients are successful in 
reversing their depressive symptoms with treatment (Marken & Munro, 2000; Rush et al. 2004). 
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Table 1. DSM-5 criteria for major depressive disorder 
Symptom Frequency requirements 
Depressed mood (subjective or observed) Most of the day, nearly every day 
Loss of interest or pleasure (anhedonia) Most of the day, nearly every day 
Change in weight or appetite Appetite: nearly every day 
Insomnia or hypersomnia Nearly every day 
Psychomotor retardation or agitation Nearly every day 
Loss of energy or fatigue Nearly every day 
Worthlessness or guilt Nearly every day 
Impaired concentration or indecisiveness Nearly every day 
Thoughts of death or suicide attempt Thoughts: recurrent 
Suicide attempt: any 
At least five symptoms must be present during the same two-week period and one must be either 
depressed mood, or loss of interest or pleasure (symptoms are summarized here; for use in a 
clinical setting, refer to the DSM-5 manual; American Psychiatric Association, 2013; Uher et al., 
2014). 
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Treatment of depression 
Clinicians may decide to treat depressed patients with pharmacological treatments, non-
pharmacological treatments, or both; a commentary on the factors important for this decision are 
beyond the scope of the present study, however, the Sequenced Treatment Alternative to Relieve 
Depression (STARED) multicenter trial offers insight on supplementation strategies or the use of 
non-pharmacological treatments (see Rush et al., 2004). For a patient’s initial episode of 
depression, a treatment regimen that includes both medication and therapy is the most successful 
regimen option for treating depressive symptoms (Bandelow et al., 2015). Medication alone is 
more successful than therapy alone, and physical exercise or taking a placebo is better than doing 
nothing (Bandelow et al., 2015). Treatment of depression may include administration of 
monoaminergic antidepressant drugs, generally classified as selective serotonin reuptake 
inhibitors (SSRIs), tricyclic antidepressants (TCAs), or monoamine oxidase inhibitors (MAOIs) 
(Williams et al., 2000; Rush et al., 2004). SSRIs may be chosen as an initial treatment because of 
the higher tolerability and near absent risk for overdose lethality observed with SSRI treatment 
(MacGillivray et al., 2003). Unfortunately, between 34% and 46% of patients do not respond to 
treatment with these drugs (MacGillivray et al., 2003; Hillhouse & Porter, 2015). In addition, the 
effectiveness of monoaminergic drugs, newer and older, does not significantly differ (Williams 
et al., 2000). Moreover, therapeutic effects associated with monoaminergic drugs require daily 
administration, and therapeutic effects may be delayed by 2-8 weeks; this delay may further 
worsen disability-adjusted life year loss (Marken & Munro, 2000; MacGillivray et al., 2003). If a 
patient has no improvement after the first-line treatment, then clinicians may augment with a 
second component (e.g., cognitive behavioral therapy) or replace with another treatment (Rush et 
al., 2004). A patient with depression may be considered to have treatment-resistant depression 
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when six-weeks of continuous antidepressant treatment fails to produce alleviate symptoms 
(Fava & Davidson, 1996). Treatment options for patients beyond or in conjunction with 
medication may include psychotherapy and electroconvulsive therapy (Bandelow et al., 2015). 
Patients diagnosed with major depressive disorder have deficits in general cognitive 
performance, attention, visual learning, and memory compared to the performance of healthy 
controls (Roca et al., 2015). Patients with cognitive symptoms have earlier onset and longer 
episodes of depression (Papakostas, 2014). Patients with cognitive symptoms are further 
negatively impacted by treatment with monoaminergic drugs, like SSRIs, which have been 
reported to worsen cognitive symptoms for over 50% of patients with depression (Papakostas, 
2014; Popovic et al., 2015). The study by Papakostas (2014) reported that treatment with 
Paroxetine, Fluoxetine, Citalopram, Escitalopram, and Sertraline (all SSRIs) worsened cognitive 
symptoms for patients diagnosed with depression. Development of treatment options with fewer 
side-effects, like worsening memory, is imperative for health outcomes (Papakostas, 2014). 
Non-pharmacological treatment options, like electroconvulsive therapy, are also effective 
in treating depression (Fink, 2001). Notably, electroconvulsive therapy is effective for about 
50% of patients with treatment-resistant major depressive disorder (Dierckx et al., 2012); 
however, clinical use of electroconvulsive therapy is limited by adverse side-effects like 
impaired memory and confusion (Calev et al., 1991; Kujala et al., 2002). Another emerging non-
pharmacological treatment, transcranial magnetic stimulation, has potential as a non-invasive and 
low-cost treatment (George & Post, 2011). A recent meta-analysis of randomized, double-
blinded, and sham-controlled trials reported mixed results with active transcranial magnetic 
stimulation (Moffa et al., 2019). The effect of transcranial magnetic stimulation on memory or 
cognition was not measured and the researchers recommended further large scale randomized 
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clinical trials (Moffa et al., 2019). Like monoaminergic treatment, transcranial magnetic 
stimulation or therapy may not work for every patient and the reasons for this are unclear 
(MacGillivray et al., 2003; Bandelow et al., 2015; Moffa et al., 2019). 
Pathogenesis of depressive symptoms 
Depressive symptoms and depressive-like behavior, for which chronic exposure to 
stressful stimuli is a major risk factor, are associated with changes in the structure and function 
of the mammalian (human and rodent) nervous system (Citri & Malenka, 2008; Grandjean et al., 
2016; Ochs-Ross et al., 2019). The neural plasticity mechanisms important for these changes 
play an important role in the ability of the nervous system to change in response to 
environmental stimuli, behavior, thought, and emotions (Citri & Malenka, 2008; Ganguly & Poo, 
2013). These changes can be observed at multiple levels, from in vivo animal behavior to a single 
neuron, and the molecular mechanisms responsible are well conserved across all organisms 
(Hegde, Goldberg, & Schwartz, 1993; Kültz, 2005). Preclinical research, whether with sea slugs 
or rodents, allows researchers to make inferences from the effects of stressful stimuli and 
antidepressants on non-human animals for human health (Hegde, Goldberg, & Schwartz, 1993; 
Duman et al., 2016). Both human and animal studies expand understanding of the mechanisms 
underlying depression. 
Depressive symptoms and depressive-like behaviors are associated with changes in the 
hippocampus, prefrontal cortex, amygdala, and other brain regions in both humans and mice, 
respectively (Liston et al., 2006; Drevets et al., 2008; Liu et al., 2017; Ochs-Ross et al., 2019). 
Post-mortem human studies have indicated that depressive symptoms are associated with 
reduced grey matter within the hippocampus, prefrontal cortex, amygdala, and other brain 
regions (Drevets et al., 2008; Kang et al., 2012). Preclinical studies also have demonstrated that 
EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 13 
stressful stimuli cause protein degradation in these same brain regions (McEwen, 2001; Ulrich-
Lai & Herman, 2009). Conversely, protein synthesis is positively correlated with successful 
treatment of depression and therapeutic effects with monoaminergic drug treatment (Drevets, 
Price, & Furey, 2008; Kang et al., 2012). 
Brain-derived neurotrophic factor (BDNF) is one protein implicated in the cellular 
processes associated with depressive symptoms (Duman et al., 1999; Duman et al., 2016). This 
protein, BDNF, is important for maintaining existing neurons and the growth of new neurons and 
new synapses (Huang & Reichardt, 2001). Exposure to stressful stimuli and the stress hormone 
corticosterone have both been demonstrated to decrease expression of BDNF (Warner‐Schmidt 
and Duman 2006). Decreased BDNF expression leads to decreases in dendritic spines, which are 
small protrusions on a neuron’s dendrite that help transmit electrochemical signals between 
neurons (Duman and Duman 2015). The medication ketamine, historically used for anesthesia, 
has been demonstrated to rapidly increase dendritic spine numbers via increasing BDNF 
expression (Duman and Duman 2015). Taken together, these findings support the hypothesis that 
depression may result from inappropriate neuronal structuring. 
Ketamine 
In 2019, the U.S. Food and Drug Administration’s (FDA) approval of SPRAVATO™, or 
(S)-ketamine (esketamine), marked the introduction of a new rapid-acting antidepressant drug 
(FDA, 2019). Unlike all other FDA approved antidepressant drugs, (S)-ketamine is an 
arylcyclohexylamine, a noncompetitive potent N-methyl-D-aspartate receptor (NMDAR) 
antagonist, and is effective within hours following a single dose (Marken & Munro, 2000; Roth 
et al., 2013). Whether or not NMDAR antagonism is important for the antidepressant effects of 
(S)-ketamine remains unclear, however (Zanos et al., 2016; Yamaguchi et al., 2018). One 
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hypothesis, the disinhibition hypothesis, proposes that reversal of depressive symptoms is 
produced by ketamine inhibiting NMDARs on gamma-Aminobutyric acid (GABA) producing 
interneurons. The inhibition of GABAergic interneurons is hypothesized to disinhibit 
glutamatergic pyramidal neurons and increase synaptic protein translation, which leads to newly 
synthesized proteins like BDNF (Aleksandrova, Wang, & Phillips, 2017). Future studies should 
further examine this hypothesis. 
Despite an incomplete understanding of the mechanism of action, the potential benefits of 
(S)-ketamine led the FDA to designate (S)-ketamine as a breakthrough therapy, meaning the 
FDA grants priority to the development of (S)-ketamine as a therapeutic drug for treatment-
resistant depression (Ionescu & Papakostas, 2017; FDA, 2019). One benefit over traditional 
monoaminergic antidepressants, which require daily drug administration, is that treatment with 
(S)-ketamine begins with drug administration twice a week for four weeks and then shifts to once 
a week or once every two weeks (Marken & Munro, 2000; Janssen Pharmaceutical Companies, 
2019). The more infrequent dosing may be made possible by long-lasting changes in the 
structure of neurons and synapses (Duman and Duman 2015). In a recent phase 3, double-blind, 
randomized clinical study with 297 adults, treatment-resistant patients treated with intranasal (S)-
ketamine plus oral antidepressant (an SSRI) were significantly less likely to experience relapse 
of depressive symptoms than patients treated with an intranasal placebo plus oral SSRI (Patel & 
Holle, 2019). Excitement for a better alternative treatment, however, is lessened by reports 
indicating that some patients may experience severe side effects like hallucinations, reduced 
cognitive functioning, and nausea for a few hours after (S)-ketamine treatment (Zanos et al., 
2018; Patel & Holle, 2019). Other arylcyclohexylamines, like (R)-ketamine and (2R,6R)-
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hydroxynorketamine may have reduced effect on cognition than (S)-ketamine (Yang et al., 2016; 
Zanos et al., 2018), but that remains to be determined. 
Ketamine, or (R,S)-ketamine, is a racemic mixture with equal parts of two stereoisomers 
((R)-ketamine and (S)-ketamine, see Figure 1, left panel). Stereoisomerism, or spatial isomerism, 
is a term used to describe molecules with the same molecular formula, but different spatial 
orientation (International Union of Pure and Applied Chemistry, McNaught, & Wilkinson, 
1997). (R)-Ketamine and (S)-ketamine are optical isomers; a subtype of stereoisomerism where 
the two molecules are mirror images of one another but are non-superimposable (e.g. human 
hands are a common macro example). (R)-Ketamine and (S)-ketamine are identical in molecular 
formula and only differ in the direction they rotate in space; R or S, referring to Latin Rectus for 
right, clockwise, or Latin Sinister for left, counterclockwise, respectively (International Union of 
Pure and Applied Chemistry, McNaught, & Wilkinson, 1997). Furthermore, (R,S)-norketamine 
and (2R,6R;2S,6S)-hydroxynorketamine are two major metabolites of (R,S) ketamine, and each 
have distinct stereoisomers (see Figure 1, right two panels). These stereoisomers, like other 
stereoisomers, have differing effects on biological entities (PubChem, 2020). Like the isomers of 
ketamine, the isomers of the metabolites (i.e., (R)-norketamine, (S)-norketamine, (2S,6S)-
hydroxynorketamine, and (2R,6R)-hydroxynorketamine, see Figure 1, right two panels) may 
differ in antidepressant efficacy. For example, one preclinical study reported greater 
antidepressant efficacy with (2R,6R)-hydroxynorketamine treatment over (2S,6S)-
hydroxynorketamine in the forced swimming test (FST; Zanos et al., 2016). Other preclinical 
studies have reported mixed antidepressant effects with the metabolites in the FST (Sałat et al., 
2015; Yamaguchi et al., 2018; Xiong et al., 2019). While no controlled clinical trials with 
ketamine’s metabolites have been published, a recent open-label pilot study with seven 
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treatment-resistant depression patients was conducted with (R)-ketamine (arketamine) in Brazil 
(Leal et al., 2020). Following a single intravenous injection of 0.5 mg/kg arketamine, rapid and 
robust antidepressant effects were evident in all seven subjects, peaking at 240 minutes and 
persisting in six of the patients for seven days. A measure of the dissociative effects of 
arketamine were minimal or non-existent for six patients with one patient displaying a brief 
increase in effects at 40 minutes post-infusion. The authors concluded that “Arketamine might 
produce fast-onset and sustained effects humans with favorable safety profile, like previously 
reported with animals; further controlled trials are needed.” Obviously, controlled double-blind 
clinical trials will the necessary to determine the validity of these preliminary findings. There 
also are plans to conduct clinical trials with (2R,6R)-hydroxynorketamine (Thomas, 2018). 
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Figure 1. Ketamine metabolic pathway - simplified 
 
Figure 1 represents the metabolic pathway from (R, S)-ketamine to (R, S)-norketamine or (2R,6R;2S,6S)-hydroxynorketamine. Below 
each racemic mixture are the isomers. Chemical structure images provided by the PubChem open source database (Kim et al., 2019). 
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Determining which mechanism of action is responsible for its antidepressant effect may 
be difficult because (R,S)-ketamine is a “dirty” drug. A dirty drug is an informal term in 
pharmacology for drugs that bind to many different molecular targets. Beyond NMDAR 
antagonism, (R,S)-ketamine has been reported to be an antagonist at nicotinic acetylcholine 
receptors, an agonist at dopamine receptors, an antagonist at serotonin receptors, and an agonist 
at opioid receptors (see table 3 in Zanos et al., 2018). Further compounding the difficulty in 
ascertaining mechanism of action is that the ketamine isomers differ in their respective receptor 
binding profiles. For instance, (S)-ketamine has greater affinity for NMDARs than does (R)-
ketamine (Zanos et al., 2016). Interestingly, the ketamine metabolite (2R,6R)-
hydroxynorketamine does not bind to NMDARs (Zanos et al., 2016). Current evidence suggests 
that (2R,6R)-hydroxynorketamine appears to be a more selective drug than (R,S)-ketamine; one 
type of molecular target for HNK has been identified thus far: nicotinic acetylcholine receptors 
(Moaddel et al., 2013, Zanos et al., 2018). Further, all drugs discussed in the present study have 
actions on the nicotinic acetylcholine receptor; thus, this receptor may be important for the 
antidepressant effects seen in the present study. 
One known clinical trial has tested a α7 nicotinic acetylcholine receptor agonist 
(Gandelman et al., 2018). Gandelman et al. (2018) examined the effect of the daily use of 
transdermal nicotine patches among patients with late-life depression in a recent open-label 
study. Participants were placed on a dose escalation regimen from 3.5mg/day to a maximum of 
21mg/day over the course of 12 weeks. Study outcomes included self-reported mood and 
cognitive symptoms. Results indicated that 86.7% participants (13 of 15) exhibited less severe 
depressive symptoms and improved cognitive performance over the 12 weeks (Gandelman et al., 
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2018). Future double-blind randomized clinical trials may support or refute the role of nicotinic 
acetylcholine receptors and/or arylcyclohexylamines on mood and cognition. 
Preclinical behavioral assays 
Preclinical research is the first step in assessing novel candidate molecules for efficacy 
and safety. Historically, preclinical behavioral assays have been foundational techniques to 
screen monoaminergic antidepressants, like SSRIs, TCAs, or MAOIs, for antidepressant-like 
effects (Williams et al., 2000; Krishnan & Nestler, 2011). The distinction between human and 
non-human animal, antidepressant effects and antidepressant-like effects, respectively, is made 
to caution researchers away from anthropomorphic language and toward objectivity (Shapiro, 
1993). The differential-reinforcement-of-low-rate (DRL) task is one behavioral assay used to 
screen for antidepressant-like effects (O’Donnell et al., 2005).  
The differential-reinforcement-of-low-rate procedure does not stress subjects like 
despair-based assays (i.e. the FST and the tail suspension test; TST). The DRL task uses an 
operant conditioning procedure to train subjects to withhold a response for a predetermined 
amount of time, or inter-response time requirement, and then pressing a lever for presentation of 
the reinforcer (i.e. food reward). Importantly, the DRL task is not a model of depression, rather, 
it is used to screen antidepressant drugs. That said, increased impulsivity is positively correlated 
with severity of depressive symptoms in humans and antidepressant drugs may decrease 
impulsivity in laboratory animals (O’Donnell et al., 2005). The primary outcomes (dependent 
variables) in the DRL task are total responses and total reinforcers. Compared to control 
conditions, an antidepressant drug would be hypothesized to increase the number of reinforcers 
and to decrease the number of responses. Premature lever responses, before the inter-response 
time requirement is met, will reset the inter-response time requirement will not result in 
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presentation of reinforcement. The inter-response time requirement is gradually increased 
throughout training in the differential-reinforcement-of-low-rate task to a terminal value.  
A 72-second interval has been used successfully to screen SSRIs and other 
monoaminergic antidepressant drugs (O’Donnell et al., 2005). Sanger and Blackman (1989) 
reviewed the utility of the DRL 72s operant task for screening antidepressant drugs and drugs 
from other classifications. They cited studies that tested 18 different tricyclic and MAOI 
antidepressant drugs. All of these drugs produced an antidepressant-like profile by dose-
dependently increasing reinforcers and decreasing responses. In contrast, drugs from other 
classes, including alcohol, pentobarbital (barbiturate), chlordiazepoxide (anxiolytic), morphine 
(opiate), chlorpromazine and haloperidol (typical antipsychotics), clozapine (atypical 
antipsychotic), and diphenhydramine (antihistamine) did not produce an antidepressant-like 
profile. The only antidepressant that Sanger & Blackman (1989) reported as a false negative was 
bupropion, which is an atypical antidepressant that acts as a norepinephrine–dopamine reuptake 
inhibitor. A more recent review by O’Donnell et al. (2005) also reported that selective serotonin 
reuptake inhibitors and norepinephrine reuptake inhibitors, as well as a number of atypical 
antidepressants increase reinforcers and decrease responses in the DRL 72s task. They also 
reported that drugs from other psychotherapeutic classes (e.g. anxiolytics, opiates, etc.) do not 
generally produce antidepressant-like effects in the DRL 72s task. They concluded that 
activation of noradrenergic and/or serotonergic mechanisms were responsible for producing 
antidepressant-like effects in this task (they also reported that bupropion is a false negative in the 
DRL procedure). 
(R,S)-Ketamine also has been reported to produce significant antidepressant-like effects 
in the 72-second DRL task (Hillhouse et al., 2014). Hillhouse et al. (2014) demonstrated that 
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10.0 mg/kg (R,S)-ketamine significantly increased reinforcers and reduced responses in rats. 
Further, D-amphetamine produced a psychostimulant effect in the DRL task, decreasing the 
number of reinforcers and increasing the number of responses. This indicates that the DRL task 
may have advantages for screening antidepressant drugs because stimulant-like drugs do not 
produce false-positives (Hillhouse et al., 2014). No studies to date have reported on the effects of 
the ketamine isomers (R)-ketamine, (S)-ketamine, or the ketamine metabolite (2R,6R)-
hydroxynorketamine in the DRL 72-second task. Other antidepressant screening assays include 
FST and TST, which are both behavioral despair-based assays. 
FST and TST measure the effects of antidepressant drugs on animals faced with an 
inescapable stressor (Petit-Demouliere, Chenu, & Bourin, 2005; Cryan, Mombereau, & Vassout, 
2005). FST, also known as Porsolt’s test or behavioral despair test, is initiated by placing an 
animal in an inescapable water filled chamber (Porsolt, Le Pichon, & Jalfre, 1977; Porsolt, 
Bertin, & Jalfre, 1977). A drug-naïve animal is hypothesized to adopt an immobile posture more 
quickly and retain immobility for longer than an animal treated with an efficacious 
antidepressant drug. This behavior, immobility, is often referred to as a depressive-like behavior 
and is believed to reflect an involuntary defeat strategy phylogenetically consistent with human 
depression (Anisman & Zacharko, 1990; Sloman, 2008). TST is also based on the observation 
that animals will adopt an immobile posture when faced with an inescapable stressor (Thierry, 
Steru, Chermat, & Simon, 1984). During TST, rodents are hung by their tail for a short session 
(typically 6 minutes), and they will eventually develop an immobile posture (i.e. the animals stop 
struggling to escape). The length of immobility (typically measured in seconds) can then be 
compared between treatment groups (Cryan et al., 2005). In sum, an efficacious antidepressant 
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drug would be hypothesized to reduce immobility in both tests, and this is inferred to be an 
antidepressant-like effect. 
FST and TST are high-throughput screening assays with high interlaboratory reliability. 
Both assays measure unconditioned behavior and require minimal equipment. The validity and 
translatability of FST and TST is not without criticism. For example, drugs with stimulant-like 
effects may produce false positives and drugs with sedative-like effects may produce false 
negatives (Steru et al. 1985; Slattery and Cryan 2012). Another major criticism is that 
monoaminergic drugs require repeated administration in humans to reverse depressive 
symptoms. In these preclinical screening assays, FST and TST, monoaminergic drugs may be 
given once before the session and an antidepressant-like effect is then observed (Carey et al., 
2017). The disconnect between acute and repeated antidepressant drug administration also 
hinders translation to human depression. 
Screening for antidepressant-like effects is important to understand potential efficacy of a 
candidate drug for treating human depression; however, understanding the subjective effects of 
drugs can also be informative. Drug discrimination is a preclinical behavioral assay used to 
assess the subjective effects of novel candidate molecules. The subjective effects of a drug 
results from the drug’s actions within an organism. Therefore, understanding the subjective 
effects of a drug can be informative of the drug’s actions, as subjective effects of drugs are 
usually (but not always) mediated by relatively specific actions at central neurotransmitter 
receptors (Young, 2009). Drug discrimination has allowed researchers to gain insight on the 
subjective effects and pharmacology of drugs for over 50 years (Young, 2009; Porter, Prus, and 
Overton, 2018). In this task, subjects are typically trained to distinguish the subjective effects of 
a drug from vehicle (two-lever drug discrimination) (Porter et al., 2005; Solinas et al., 2006). A 
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two-lever drug discrimination study, hereinafter referred to as drug discrimination, commonly 
relies on rodents (and other animals) trained to perform a specific operant response like lever 
pressing for a reinforcer. Pressing the drug-paired lever leads to reinforcement only during 
training sessions in which the subject was treated with the training drug. After receiving vehicle 
injections, the subjects must respond on the vehicle-paired lever in order to receive a reinforcer. 
After training is complete, and subjects accurately discriminate between the training drug or 
vehicle by choosing the condition-appropriate lever, other drugs can be administered for 
substitution testing. Reinforcement is presented after responses on either lever during test 
sessions. Other test drugs are considered to share subjective effects with the training drug if 
subjects respond on the drug-paired lever. Drugs that substitute for the training drug are then 
inferred to share subjective effects and discriminative stimulus properties with the training drug. 
A study by Zanos et al. (2016) trained mice to discriminate between 10 mg/kg (R, S)-ketamine 
and vehicle. During testing, mice were injected with 10.0 mg/kg and 50.0 mg/kg (2R,6R)-
hydroxynorketamine and were presented with the drug-paired lever and vehicle-paired lever. 
Results indicated that mice responded primarily on the vehicle-paired lever (Zanos et al., 2016). 
Thus, it was inferred that (2R,6R)-hydroxynorketamine does not share subjective effects or 
discriminative stimulus properties with 10 mg/kg (R, S)-ketamine. Further, mice do not self-
administer (2R,6R)-hydroxynorketamine, unlike (R, S)-ketamine (Zanos et al., 2016). The results 
from the drug discrimination experiment and self-administration experiment indicate (2R,6R)-
hydroxynorketamine may not share the ketamine-like abuse liability. 
Other preclinical behavioral assays are useful for assessing cognitive functions, such as 
spatial memory (Snigdha et al., 2013). Some of these assays have been demonstrated to be 
sensitive to disruption in medial prefrontal cortex and hippocampus activity (Kesner et al., 2008), 
EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 24 
which interestingly, are brain regions implicated in human depressive symptoms and rodent 
depressive-like behavior (Liston et al. 2006; Drevets et al., 2008). A study by Kesner et al. 
(2008) demonstrated that lesions in the hippocampus of trained rats caused poorer performance 
in a spatial memory recall task. Studies also have indicated that altered hippocampal function is 
associated with age-related memory deficits in humans (Yassa et al., 2011; Holden et al., 2012). 
This parallel between rodents and humans contributes to the validity of preclinical studies 
measuring spatial memory and allow for interpretation of drug effects on rodent cognitive 
functioning that may translate to humans (Snigdha et al., 2013). 
The preclinical behavioral assays used to measure the spatial memory of rodents may 
include measurements of unconditioned or conditioned behavior. Because training is not needed 
for measurements of unconditioned behavior (in contrast to conditioning tasks), these tasks allow 
for relatively quick studies and high through-put screening (Snigdha et al., 2013). One example 
is the spontaneous alternation assay, which uses a maze to measure unconditioned behavior 
(Miedel et al., 2017). The maze may be shaped as a Y, T, or + sign. The subject, commonly a 
mouse or rat, is placed in the maze and the subject can explore the entire maze. A calculated 
percentage of total arm entries and the sequence of arm entries is an outcome measured in this 
assay. Subjects with lower scores than control conditions are considered to have impairment in 
spatial memory. 
Conceptually, the spontaneous alternation assay measures the efficiency of an organism’s 
search for resources. Organisms like mice are driven by an innate curiosity to explore new 
environments (Kraeuter et al., 2019). Mice with normal spatial memory and normal activity in 
the medial prefrontal cortex and hippocampus will exhibit efficient exploration by remembering 
previously explored environments (Kesner et al., 2008; Kraeuter et al., 2019). An organism using 
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the optimal search pattern would never repeat arm entries during the same search sequence (e.g. 
arm A to arm B to arm C). Conversely, inefficient search patterns are indicative of spatial 
memory deficits. One example of an inefficient search pattern would proceed from arm A to arm 
A to arm A. 
Preclinical studies have consistently demonstrated that certain doses of (R, S)-ketamine 
reduce rodent performance in spatial memory tasks (Garfield et al., 1985; Wang et al., 2006; 
Duan et al., 2013; Khanegheini et al., 2019). The study by Garfield et al. (1985) reported that 
administration of 15 mg/kg (R, S)-ketamine and 15 mg/kg (S)-ketamine impaired performance in 
a +-shaped maze. (S)-ketamine at a dose of 15 mg/kg had the greatest effect; whereas, no deficits 
were observed with 15 mg/kg (R)-ketamine. No significant effects were observed at a dose of 7.5 
mg/kg for any of these drugs. Taken together, these findings indicate that (R)-ketamine does not 
alter normal spatial memory in mice at the same dosages of (R, S)-ketamine and (S)-ketamine. 
Nonetheless, no study has yet reported on the effects of (2R,6R)-hydroxynorketamine in the 
spontaneous alternation assay. 
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Rationale 
 The present study expanded understanding of (R,S)-ketamine and the metabolite (2R,6R)-
hydroxynorketamine. One important issue is that the antidepressant-like effects of the metabolite 
(2R,6R)-hydroxynorketamine treatment is disputed. Zanos et al. (2016) was the first study to 
report on the antidepressant-like effects of (2R,6R)-hydroxynorketamine in FST. Some 
preclinical studies have supported the findings by Zanos et al. (2016) by indicating significant 
antidepressant-like effects with (2R,6R)-hydroxynorketamine (Pham et al., 2018; Zanos et al., 
2019), while other studies have reported finding no antidepressant-like effects (Shirayama & 
Hashimoto, 2017; Yang et al., 2017; Yamaguchi et al., 2018; Xiong et al., 2019). None of these 
studies, nor any other study to date, have used the DRL task to assess the antidepressant-like 
effects (2R,6R)-hydroxynorketamine. In this task, (R,S)-ketamine has been reported to produce 
antidepressant-like effects in rats (Hillhouse et al., 2014), however, no studies have reported on 
the effects of the ketamine isomers (R)-ketamine, (S)-ketamine or the metabolite (2R,6R)-
hydroxynorketamine in the DRL task. In the present study, the aim of experiment 1 was to 
measure the effects of (R,S)-ketamine, its isomers (R)-ketamine, (S)-ketamine, and the metabolite 
(2R,6R)-hydroxynorketamine in the DRL task. Experiments 2 and 3 were designed to measure 
other important behavioral effects of (R,S)-ketamine, its isomers, and the metabolite (2R,6R)-
hydroxynorketamine. 
 (R,S)-Ketamine was approved as a dissociative anesthetic in 1970 and reports of abuse of 
ketamine began to appear as early as 1971 (see Siegel 1978). Reports of (R,S)-ketamine abuse 
continued throughout the 1980s and 1990s (e.g. Kamaya & Krishna 1987) and in 1999 the DEA 
designated (R,S)-ketamine as a Schedule III therapeutic drug recognizing its abuse liability. A 
number of reviews and commentaries have addressed the recreational use and abuse potential of 
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(R,S)-ketamine (Expert Committee of Drug Dependence, WHO 2014; Liu et al. 2016; Sassano-
Higgins et al 2016; Hillhouse et al., 2019). Recent studies (both preclinical and clinical) on the 
use of ketamine as a rapid treatment for depression typically mention abuse liability as a possible 
concern (Zanos et al., 2018; Patel & Holle, 2019). No study to date has reported whether 
(2R,6R)-hydroxynorketamine is abused by humans. 
Unlike (R,S)-ketamine, mice do not self-administer (2R,6R)-hydroxynorketamine (Zanos 
et al., 2016). This difference may be due to differences in the subjective effects associated with 
each drug. (2R,6R)-hydroxynorketamine may lack the ketamine-associated subjective effects that 
lead to abuse (Zanos et al., 2016). Drug discrimination is a useful assay for helping to identify 
the potential abuse liability of drugs. Drugs of abuse typically produce strong subjective effects 
in both humans and animals and to the extent that these subjective effects relate to abuse 
liability, studying the subjective effects (i.e., discriminative stimulus properties) of drugs in 
animals provides a good translational approach to this problem that has application to potential 
abuse issues in humans. Thus, testing novel candidate molecules for shared subjective effects 
with drugs known to be abused by humans is an important step in medication development. 
To understand the subjective effects of (R,S)-ketamine, a drug discrimination study was 
conducted in Experiment 2. Previously, Zanos et al. (2016) trained mice to discriminate between 
10 mg/kg (R,S)-ketamine and saline to test whether (2R,6R)-hydroxynorketamine shares 
discriminative stimulus properties with (R,S)-ketamine. After training, when mice were tested 
with (2R,6R)-hydroxynorketamine, results indicated that (2R,6R)-hydroxynorketamine (10.0 
mg/kg and 50.0 mg/kg doses) did not share discriminative stimulus properties with a 10 mg/kg 
(R,S)-ketamine training dose. These results suggested that (2R,6R)-hydroxynorketamine lacks the 
abuse potential associated with (R,S)-ketamine. Zanos et al. (2016) did not test (R)-ketamine and 
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(S)-ketamine in that study. Training dose has been shown to be an important determinant of the 
properties of discriminative stimuli and different patterns of substitution for test drugs may be 
evident with different training doses of the training drug (see Stolerman et al. 2011). Therefore, 
the current study used a lower training dose, 5.0 mg/kg (R,S)-ketamine, in a two-lever drug 
discrimination procedure to determine if this altered the discriminative stimulus properties of 
(R,S)-ketamine and whether (2R,6R)-hydroxynorketamine shared discriminative stimulus 
properties with (R,S)-ketamine at this lower training dose. In addition, we tested the ketamine 
isomers, (R)-ketamine and (S)-ketamine to determine if they share discriminative stimulus 
properties with (R,S)-ketamine. 
Finally, the present study measured the effects of (R,S)-ketamine, (R)-ketamine, (S)-
ketamine, and (2R,6R)-hydroxynorketamine on cognition 24 hours after treatment. (R,S)-
Ketamine treatment (20 mg/kg and 30 mg/kg) has been reported to produce significant cognitive 
impairment in rodent spatial memory 15 minutes after treatment (Verma & Moghaddam, 1996). 
(S)-Ketamine, but not (R)-ketamine, also has been demonstrated to produce deleterious effects on 
cognition 5 minutes after treatment (Garfield et al., 1985). Also, the recent approval of (S)-
ketamine for treatment-resistant depression, has raised concerns by some that some patients may 
experience reduced cognitive functioning for several hours after each treatment (Zanos et al., 
2018; Patel & Holle, 2019). No published study has reported on the cognitive effects of (2R,6R)-
hydroxynorketamine in either animals or humans.  
An ideal antidepressant drug improves depressive symptoms without hindering cognitive 
performance. Furthermore, a longer pretreatment time to measure effects on cognition may be 
warranted because multiple studies have demonstrated that the antidepressant-like effects 
associated with (R,S)-ketamine treatment have been observed 24-hours (and longer) after 
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treatment (Duman et al., 2016; Franceschelli et al., 2015; Fukumoto et al., 2017; Zanos et al., 
2019). To this end, the present study treated subjects 24 hours before testing in the Y-maze.  
Taken together, these gaps in understanding provide a strong impetus to test (R,S)-
ketamine, its isomers (R)-ketamine, (S)-ketamine, and the metabolite (2R,6R)-
hydroxynorketamine in the DRL task to test for antidepressant-like effects, a drug discrimination 
study with a lower 5.0 mg/kg (R,S)-ketamine training dose to test for shared subjective effects 
(and potential for abuse liability), and a spontaneous alternation Y-maze task to test for cognitive 
effects. 
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Aims & hypotheses 
Aim 1 (Experiment 1): Differential-reinforcement-of-low-rate (DRL) 
 To determine if (R,S)-ketamine, the ketamine isomers, (S)-ketamine and (R)-ketamine, 
and the ketamine metabolite (2R,6R)-hydroxynorketamine produce an antidepressant-like profile 
similar to (R,S)-ketamine in the differential-reinforcement-of-low-rate 72-second task (DRL 72-
sec) with C57BL/6 mice. 
 Hypothesis 1: (R,S)-ketamine will produce significantly fewer mean responses and 
significantly more mean reinforcers compared to vehicle. The current study tested doses of 5.0, 
10.0, 17.8, and 32.0 mg/kg (R,S)-ketamine. This dose range was based on a previous study in rats 
by Hillhouse et al. (2014). In that study (R,S)-ketamine demonstrated an antidepressant-like 
profile at 10.0 mg/kg (R,S)-ketamine, but not at 1.0 and 3.2 mg/kg doses of (R,S)-ketamine. 
Hypothesis 2: (S)-ketamine and (R)-ketamine will produce significantly fewer mean 
responses and significantly more mean reinforcers compared to vehicle. Changes in mean 
responses and mean reinforcers are hypothesized to be dose-dependent: thus, doses of 10.0, 17.8, 
and 32.0 mg/kg were tested for each isomer.  
Hypothesis 3: (2R,6R)-hydroxynorketamine will produce significantly fewer mean 
responses and significantly more mean reinforcers compared to vehicle. Zanos et al. (2016) 
demonstrated (2R,6R)-hydroxynorketamine can be safely administered in doses above 56.0 
mg/kg. Therefore, a dose of 56.0 mg/kg was tested. 
Aim 2 (Experiment 2): Drug discrimination 
 To determine if 0.625, 1.25, 2.5, 5.0, 10.0 mg/kg (R)-ketamine, 0.3125, 0.625, 1.25, 2.5, 
5.0 mg/kg (S)-ketamine, and 10.0 mg/kg, 56.0 mg/kg (2R,6R)-hydroxynorketamine share 
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discriminative stimulus properties with 5.0 mg/kg (R,S)-ketamine in a two-lever drug 
discrimination task. 
 Hypothesis 1: C57BL/6 mice will discriminate between 5.0 mg/kg (R,S)-ketamine and 
vehicle in a two-lever drug discrimination task. Successful discrimination is indicated when 
subjects respond ≥80% on the drug paired-lever when treated with 5.0 mg/kg (R,S)-ketamine and 
< 20% on the drug paired-lever when treated with vehicle. A dose response generalization curve 
was determined by testing 0.625, 1.25, 2.5, 5.0, and 10.0 mg/kg (R,S)-ketamine.  
 Hypothesis 2: The ketamine isomers (R)-ketamine and (S)-ketamine, but not the ketamine 
metabolite (2R,6R)-hydroxynorketamine will share discriminative stimulus properties with (R,S)-
ketamine. No studies have reported on whether (R)-ketamine, (S)-ketamine, or (2R,6R)-
hydroxynorketamine will substitute for 5.0 mg/kg (R,S)-ketamine in a drug discrimination task. 
Aim 3 (Experiment 3): Spontaneous alternation in a Y-maze 
 To determine if (R,S)-ketamine, the ketamine isomers, (S)-ketamine and (R)-ketamine, 
and the ketamine metabolite (2R,6R)-hydroxynorketamine produce cognitive deficits in 
spontaneous alternation in a Y-maze task in C57BL/6 mice. The following doses were tested: 
10.0 and 32.0 mg/kg (R,S)-ketamine; 16.0 and 32.0 mg/kg (S)-ketamine; 16.0 and 32.0 mg/kg 
(R)-ketamine; 10.0, 32.0, and 56.0 mg/kg (2R,6R)-hydroxynorketamine. Garfield et al. (1985) 
previously reported significant spatial memory impairment (spontaneous alternation in Y-maze) 
in mice after treatment with 15.0 mg/kg (R,S)-ketamine and 15.0 mg/kg (S)-ketamine. 
 Hypothesis 1: (R,S)-Ketamine and (S)-ketamine are hypothesized to significantly 
reduce % spontaneous alternation in the Y-maze task 24 hours after treatment.  
Hypothesis 2: (R)-Ketamine and (2R,6R)-hydroxynorketamine are hypothesized to not 
significantly reduce % spontaneous alternation in the Y-maze task 24 hours after treatment. 
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Methods 
All procedures were approved by the Institutional Animal Care and Use Committee at 
Virginia Commonwealth University (IACUC Protocol AM10284) and all studies were 
performed in agreement with the guide for the Care and Use of Laboratory Animals (National 
Research Council, 2011). 
Subjects 
All studies used adult male C57BL/6 mice (Envigo, Indianapolis, IN) weighing 21-32 
grams. Mice were maintained on a 12/12-hour light-dark cycle (lights on 0600 h). Mice were 
allowed two weeks to adapt the new environment before experimentation. The mice were housed 
individually in a temperature-controlled vivarium at 22-24° Celsius. Nesting material, cardboard 
tubes, and ad libitum access to water were provided in their home cage. After two weeks, mice 
were handled for 5 minutes daily for one week. 
Drug 
 All drugs were administered subcutaneously at a volume of 10 ml/kg. All drugs were 
dissolved in 0.9% saline. Doses and pretreatment times were based on previous studies in the 
literature (Hillhouse & Porter, 2014; Zanos et al., 2016) and studies in our laboratory with 
C57BL/6 mice (unpublished data). (R, S)-Ketamine was purchased from Sigma-Aldrich 
Chemical Company (St Louis, Missouri, USA). (R)-Ketamine, and (S)-ketamine were purchased 
from Cayman Chemical Company, 1180 East Ellsworth Road, Ann Arbor, MI 48108 USA. 
(2R,6R)-Hydroxynorketamine was graciously provided in collaboration with the National Center 
for Advancing Translational Sciences in Bethesda, Maryland, USA.  
Experiment 1: Differential-reinforcement-of-low-rate (DRL) 
Subjects 
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Free-feeding (100%) bodyweights were established for nine adult male C57BL/6 mice by 
using the highest free-feeding body weight before withdrawing free access to food. Their weights 
were maintained at 85-90% of their 100% body weights via food restriction. Because this study 
lasted for 18 months, subjects were placed on ad libitum food and not trained or tested for two 
weeks during month 6 and month 12. The new 100% body weights were established at the end of 
each free-feeding period.  
Materials 
Apparatus 
The DRL training and testing were conducted in six standard computer-interfaced 
operant conditioning chambers (15 cm L X 11.5 cm D X 17.5 cm H; Model ENV-307A, Med 
Associates Inc., St. Albans, Vermont, USA), each containing two retractable levers in the left 
and right position (8 cm apart) on the front panel of the operant chamber. The levers extended 
0.8 cm into the chamber and were positioned 2.5 cm above a grid floor constructed of parallel 
stainless-steel rods. Centered between them was a recessed food trough into which a liquid 
dipper delivered 0.02 mL of sweetened milk (by volume: 80 mL powdered milk, 80 mL sugar, 
and 200 mL tap water). Test chambers were housed in sound attenuating cubicles equipped with 
ventilation fans. MED-PC software (Version 4.2, Med Associates Inc.) was used to control the 
operant sessions and record data. 
Procedure 
Magazine training 
 All mice were first given two sessions of magazine training, during which the house light 
was on, but no lever was extended. Magazine training consisted of one reinforcer (i.e., sweet 
milk) being delivered non-contingently, according to a fixed-time 60s schedule for 30 min. On 
EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 34 
the third day, a 20 min single lever training session was applied, during which the mice were 
trained to press either the left or right lever under a fixed ratio 1 (FR 1) food reinforcement 
schedule, in which each level press resulted in delivery of a reinforcer. The position of the lever 
associated with the FR 1 schedule was counterbalanced, with half of the subjects assigned the 
right lever and half assigned to the left lever. The criteria for passing the FR 1 training was 30 
reinforcers delivered in 20 min. On day 7, after all mice met the criteria, the DRL training began. 
Differential-reinforcement-of-low-rate training 
 Under the DRL schedule, a response produced a reinforcer only after a specified inter-
response interval had elapsed. Responses emitted before the end of the inter-response interval 
reset the timer and did not produce a reinforcer. All DRL training and testing sessions were set to 
end at 60 min or when the animal received 50 reinforcers. The inter-response interval was 
gradually increased over 12-16 sessions; from an initial value of 4.5s, to a terminal value of 72s. 
To clarify, mice were initially trained on a DRL 4.5s schedule for the first session, and all mice 
reached the 50-reinforcer goal within the 60 min session time. The next day, the DRL schedule 
was increased to 9s. Then, the DRL schedule was increased to 18s for 2 sessions and then to 36s 
for 5 sessions. Finally, the DRL schedule was increased to the final schedule value of 72s until 
performance stabilized (the number of responses for each mouse did not vary by more than 10% 
of the mean for five or six consecutive sessions). Test sessions occurred twice weekly (typically 
Tuesdays and Fridays) with a minimum of one training session between each test session. A 
vehicle baseline, which consisted of two vehicle test days, was established before and after each 
drug test. 
 Experiment 1 used a within-subjects design; therefore, all subjects were treated with each 
test drug and dose. Testing began with (R, S)-ketamine with doses of 5.0 mg/kg, 10.0 mg/kg, 
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17.8 mg/kg, and 32 mg/kg. Then, (S)-ketamine and (R)-ketamine were tested at 10.0 mg/kg, 17.8 
mg/kg, 32.0 mg/kg doses. Finally, (2R, 6R)-hydroxynorketamine was tested at a dose of 56 
mg/kg. All drugs were administered subcutaneously 10 minutes prior to testing. The order of 
dose was randomly counterbalanced with between two groups of subjects, one group in 
ascending doses and the other group of mice tested in descending doses. 
Data analysis 
 The dependent variables were reinforcers (total number of earned reinforcers during each 
test session) and responses (total number of responses during each test session). All data are 
expressed as means. One-way repeated measures analyses of variance (ANOVA) were 
conducted to test for statistically significant differences between each drug condition and saline. 
When the ANOVA was significant, Dunnett’s post hoc tests were used to compare the drug 
doses to saline. The criterion for significance was set at p < 0.05 and all data were analyzed using 
GraphPad Prism version 8.3 (GraphPad Software, San Diego, California, USA) on a Windows 
10 PC. 
Experiment 2: Drug discrimination 
Subjects 
Twelve adult male C57BL/6 mice (Envigo, Indianapolis, IN) weighing 21-34 grams were 
used in this study. The same acclimation and housing procedures used in experiment 1 were 
followed. The 100% bodyweights were established using the highest free-feeding body weight 
before withdrawing free access to food, and their weights were maintained at 85-90% of their 
body weights via food restriction. Experiment 2 lasted for 12 months; therefore, mice were 
placed on free feed during month 6 for 2 weeks. The new 100% body weights were established at 
the end of the free-feeding period. 
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Materials 
Apparatus 
See apparatus in Experiment 1. 
Procedure 
Magazine training  
See procedure in Experiment 1. 
Single lever training 
The mice were initially trained to lever press using a modified autoshaping procedure to 
respond on a single extended lever (the vehicle-condition appropriate lever) for 0.02 mL of 
sweetened milk (Barrett & Vanover, 2004; Vanover & Barrett, 1998). Following autoshaping of 
the lever press response, single-lever training began. A single lever (the vehicle-paired lever) 
was extended inside the chamber. Each subject was placed in the operant chamber for a 15-
minute session and trained on a FR 1 reinforcement schedule. The value of the FR was gradually 
increased over the next 11-16 sessions until FR 10 was obtained. Animals were then trained 
using errorless training, in which a single condition-appropriate lever (i.e. vehicle or drug lever) 
was extended inside the chamber. First, the mice were trained with only the vehicle lever with 
vehicle injection (10 min pre-session). After response rates stabilized under vehicle condition (5 
sessions), the mice were then trained with 5.0 mg/kg (R, S)-ketamine injection (10 min pre-
session) with the opposite (i.e., drug) lever until response rates stabilized (6 sessions). All lever 
assignments were counterbalanced across mice to avoid possible confounding by olfactory cues. 
To this end, the response levers were cleaned with a 10% ethanol solution after each test session 
(Extance & Goudie, 1981). Following completion of single-lever training, two-lever drug 
discrimination training began. 
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Drug discrimination acquisition training 
During the two-lever drug discrimination training, both levers were extended into the 
operant chamber. The subjects were administered a training dose of 5.0 mg/kg (R, S)-ketamine or 
vehicle according to a double alternation sequence of drug (D) and vehicle (V) (i.e., 
DDVVDDVV). On days when the drug was administered, only responding on the drug-
associated lever was reinforced. Conversely, on days that vehicle was administered, only 
responding on the vehicle-associated lever was reinforced. A response on the incorrect lever 
before completing ten responses on the condition-appropriate lever reset the FR counter. 
Subjects received two-lever drug discrimination training until the discrimination training criteria 
were passed for five of six consecutive sessions. Successful discrimination training was 
evaluated and assessed according to three criteria: (1) the first completed fixed ratio of the FR 10 
schedule was completed on the condition-appropriate lever, (2) ≥80% of total responses made 
during the session occurred on the condition-appropriate lever, and (3) response rate for the 
session was greater than or equal to 10 responses per minute. 
Generalization and substitution testing 
Once drug discrimination training was completed, generalization testing with the training 
drug began. During test sessions, switching levers before completion of the FR10 requirement 
reset the FR counter. However, completion of the FR 10 requirement on either lever resulted in 
delivery of a reinforcer. Mice were required to pass control tests for vehicle and (R, S)-ketamine 
(according to the training criteria above) before the start of generalization dose-effect curve for 
each test drug. Additionally, mice were required to meet the training criteria for vehicle and (R, 
S)-ketamine on two consecutive training days before becoming eligible for a test day.  
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The (R, S)-ketamine generalization dose-effect curve was established with doses of 0.625 
mg/kg, 1.25 mg/kg, 2.5 mg/kg, 5.0 mg/kg, and 10 mg/kg, with subcutaneous injections 10 
minutes prior to testing. The order of dose was randomly counterbalanced with between two 
groups of mice; half of the mice were tested in ascending dose order and the other half were 
tested in descending dose order. For the tests of (R)-ketamine and (S)-ketamine, the subjects 
were randomly counterbalanced into two groups for substitution testing of (R)-ketamine and (S)-
ketamine. Subjects were treated with 0.625 mg/kg, 1.25 mg/kg, 2.5 mg/kg, 5.0 mg/kg, 10.0 
mg/kg (R)-ketamine or 0.3125 mg/kg, 0.625 mg/kg, 1.25 mg/kg, 2.5 mg/kg, 5.0 mg/kg (S)-
ketamine, 10 minutes prior to testing. For the substitution test with (2R,6R)-hydroxynorketamine, 
mice were treated with 10.0 mg/kg and 56.0 mg/kg. (2R,6R)-Hydroxynorketamine was tested 
first at 10-minute injection time and then at 60-minute injection time; the 60-minute pretreatment 
time for (2R,6R)-hydroxynorketamine was chosen for exploratory purposes. 
Data analysis 
The Med-PC software was programmed to calculate the percent drug-lever responding (% DLR) 
on the condition-appropriate lever by dividing the number of responses on that lever by the total 
number of responses on both levers and then multiplying the result by 100. Responses per minute 
were calculated by taking the total number of responses on both levers and dividing by 15 mins 
(i.e. the session length). Full substitution to the (R, S)-ketamine stimulus cue was defined as ≥ 
80% DLR on the (R, S)-ketamine lever. Partial substitution to (R, S)-ketamine stimulus cue was 
defined as ≥ 60% DLR. Vehicle-appropriate responding was defined as < 20% DRL. One-way 
repeated measures analyses of variance (ANOVA) were conducted on response rates to test for 
statistically significant differences between each drug condition and saline. When the ANOVA 
was significant, Dunnett’s post hoc tests were used to compare the drug doses to saline. The 
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criterion for significance was set at p < 0.05 and all data were analyzed using GraphPad Prism 
version 8.3 (GraphPad Software, San Diego, California, USA) on a Windows 10 PC. 
Experiment 3: Spontaneous alternation in a Y-maze 
Subjects 
One-hundred and twenty adult male C57BL/6 mice (Harlan, Indianapolis, IN) weighing 
between 19 and 26 g, were used in this experiment. The same acclimation and housing 
procedures used in experiments 1 and 2 were followed, the only exception in Experiment 3 was 
that the mice were never food deprived. Upon arrival, mice habituated to the vivarium for two 
weeks before experimentation. Mice were maintained on a 12/12-hour light-dark cycle (lights on 
0600). Mice were group housed with four mice per cage. Nesting material, cardboard tubes, and 
ad libitum access to water were provided in their home cage. After two weeks, mice were 
handled for 5 minutes daily for one week. Mice were aged 8-14 weeks for testing. 
Materials 
Apparatus 
 The apparatus was a 3-arm maze and each arm spaced at an angle of 120 degrees (Figure 
2). Each arm was 35 cm long, 7 cm wide, and the walls were 20 cm tall. The arms were clearly 
labelled ‘A’, ‘B’, and ‘C’. The walls and floor are clear acrylic and were painted white. To avoid 
shadows, the maze was well lit from above. Each session was digitally recorded with a GoPro 
Hero 7 camera. The maze was cleaned with a 10% ethanol solution between each session. 
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Figure 2. Y-maze was made from clear acrylic, cut with a computer numerical control router, and 
polylactic acid 3D printed components.  
Procedure 
 Spontaneous alternation is an unconditioned behavior. Therefore, no training is required 
to test short-term memory in this procedure. Mice were habituated to the room with the maze for 
at least 30 minutes prior to testing. After habituation, video recording began, and each mouse 
was gently placed into the same maze arm to start each test session. The maze was cleaned with 
10% ethanol between sessions to reduce the likelihood of olfactory cues carry-over between 
sessions. Test sessions lasted for 10 minutes, during which time the mice could freely explore the 
maze. 
 A between-subjects design was used with mice randomly assigned to ten groups (12 per 
group); saline, (R, S)-ketamine 10.0 mg/kg, (R, S)-ketamine 32.0 mg/kg, (2R,6R)-
hydroxynorketamine 10.0 mg/kg, (2R,6R)-hydroxynorketamine 32.0 mg/kg, (2R,6R)-
hydroxynorketamine 56.0 mg/kg, (R)-ketamine 16.0 mg/kg, (R)-ketamine 32.0 mg/kg, (S)-
ketamine 16.0 mg/kg, and (S)-ketamine 32.0 mg/kg. All drugs were administered subcutaneously 
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24 hours prior to testing because we wanted to assess whether cognitive deficits persisted beyond 
elimination of the drug (Rajagopal et al., 2016). Persistent effects on cognition would indicate a 
neuronal structural change and dysregulation of network activity in the brain beyond acute 
effects while the drug is in the organism. This is important for treating human patients. Ideally, 
treatment would not cause long-term cognitive impairments to patients who may already be 
suffering from cognitive deficits associated with depression. 
Data analysis 
 Sessions were digitally recorded and then arm entries were scored by one undergraduate 
student masked to the test conditions. Then, a second student (also blinded to test conditions) 
would watch the videos and ensure arm entries were scored correctly. A mouse was considered 
to have made a spontaneous alternation when all four paws entered a different arm (i.e. leaving 
the center of the maze and crossing the threshold to a maze arm) of the maze in three consecutive 
alternations, or arm entries. Percent spontaneous alternation was then calculated by dividing the 
spontaneous alternation count during the 10-minute session by total number of arm entries, 
minus two, during the 10-minute session. Subtracting two arm entries from the denominator (the 
total number of arm entries) accounts for the first two arm entries, which could not have counted 
as a spontaneous alternation (Miedel et al., 2017). One-way between-subject analyses of variance 
(ANOVA) were conducted for each drug to test for statistically significant differences between 
each drug condition and the saline, vehicle condition (which was used for each analysis). When 
the ANOVA was significant, Dunnett’s post hoc tests were used to compare the drug doses to 
vehicle. The criterion for significance was set at p < 0.05 and all data were analyzed using 
GraphPad Prism version 8.3 (GraphPad Software, San Diego, California, USA) on a Windows 
10 PC.  
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Results 
Experiment 1: Differential-reinforcement-of-low-rate (DRL) 
Figure 3 shows the effects of (R,S)-ketamine on mean number of reinforcers and number 
of responses. (R,S)-Ketamine treatment produced a significant effect on reinforcers (F (4, 44) = 
9.43, p = 0.0014). A Dunnett’s multiple comparisons test indicated that 32 mg/kg (R,S)-ketamine 
significantly increased the mean number of reinforcers as compared to vehicle (p < 0.0041). For 
number of responses, (R,S)-ketamine produced a significant effect (F (4, 44) = 4.27, p = 0.015). 
A Dunnett’s multiple comparisons test indicated that 32 mg/kg (R,S)-ketamine significantly 
decreased the mean number of responses as compared to vehicle (p < 0.033). 
(R)-Ketamine (Figure 4) 10.0 mg/kg, 17.8 mg/kg, and 32.0 mg/kg produced no 
significant effects on reinforcers or responses at any of the tested doses (F (3, 35) = 1.69, p = 
0.21); (F (3, 35) = 0.55, p = 0.58), respectively). (S)-Ketamine (Figure 5) produced a significant 
effect on reinforcers (F (3, 35) = 8.23, p = 0.014). A Dunnett’s multiple comparisons test 
indicated that both 17.8 mg/kg and 32.0 mg/kg (S)-ketamine significantly increased the mean 
number of reinforcers as compared to vehicle (p = 0.022, p = 0.030, respectively). For number of 
responses, (S)-ketamine produced a significant effect (F (3, 35) = 17.45, p < 0.0001). A 
Dunnett’s multiple comparisons test indicated that both 17.8 mg/kg and 32.0 mg/kg (S)-ketamine 
significantly decreased the mean number of responses as compared to vehicle (p = 0.0023, p = 
0.0006, respectively). 
The ketamine metabolite (2R,6R)-hydroxynorketamine (Figure 6), at a dose of 56 mg/kg, 
produced a significant increase in the mean number of reinforcers (t (8) = 2.8, p = 0.023) and a 
significant decrease in the mean number of responses (t (8) = 3.51, p = 0.0079). 
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Figure 3. Effects of (R,S)-ketamine on mean number of reinforcers and number of responses (n = 
9). Asterisks represent significant differences from vehicle, and all data are expressed as means + 
standard error of the mean (+SEM). The alpha level was set to 0.05. For all graphs: * = p < 0.05, 
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Figure 4. Effects of (R)-ketamine on mean number of reinforcers and number of responses (n = 
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Figure 5. Effects of (S)-ketamine on mean number of reinforcers and number of responses (n = 
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Figure 6. Effects of (2R,6R)-hydroxynorketamine on mean number of reinforcers and number of 
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Experiment 2: Drug discrimination 
Figure 7 shows the (R,S)-ketamine generalization dose effect curve for C57BL/6 mice 
trained to discriminate 5.0 mg/kg (R,S)-ketamine from vehicle. Subjects were successfully 
trained to discriminate 5.0 mg/kg (R,S)-ketamine and vehicle in a two-lever drug discrimination 
task (average 19.6 sessions; range = 8 – 29 sessions). Generalization testing with (R,S)-ketamine 
yielded an ED50 = 2.03 mg/kg (95% confidence interval (C.I.) = 1.71 – 2.42 mg/kg). (R,S)-
Ketamine (fully generalized (80% or greater responding on the drug-paired lever) at 2.5 mg/kg, 
5.0 mg/kg (the training dose), and 10.0 mg/kg (R,S)-ketamine. Responding above 80% on the 
drug-paired lever, is considered full generalization to the training dose. A one-way repeated 
measures ANOVA indicated a significant effect of treatment on the mean number of responses 
per minute (F (5, 55) = 3.66, p = 0.0063. A Dunnett’s multiple comparisons test revealed that 
0.625 mg/kg and 1.25 mg/kg (R,S)-ketamine produced small but significant increases in 
responses per minute when compared to vehicle. This increase in responses may be attributed to 
changes in locomotor behavior associated with (R,S)-ketamine treatment. (R,S)-Ketamine 
treatment has been observed to increase locomotor behavior in an open-field (Zanos et al., 2016). 
Both the (R) and (S) ketamine isomers shared discriminative stimulus properties with 
(R,S)-ketamine 5.0 mg/kg. The (R) isomer (Figure 8) fully substituted at 10 mg/kg, but not at 
lower doses (ED50 = 2.69 mg/kg, 95% C.I. = 1.43 - 5.05 mg/kg). The (S) isomer (Figure 9) fully 
substituted at 2.5 mg/kg and 5.0 mg/kg (ED50 = 1.07 mg/kg, 95% C.I. = 0.69-1.63 mg/kg). 
Neither the (R) or (S)-ketamine isomers produced any significant changes in response rates (F (5, 
25) = 1.33, p = 0.30; F (6, 36) = 1.41, p = 0.28, respectively).  
Figures 10 and 11 present results for the (2R,6R)-hydroxynorketamine substitution testing 
at 10-minute and 60-minute injection times, respectively. Both 10.0 mg/kg and 56.0 mg/kg 
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(2R,6R)-hydroxynorketamine, at 10-minute (F (2, 10) = 1.63, p = 0.24) and 60-minute 
pretreatment (F (2, 10) = 1.72, p = 0.23) failed to substitute for 5.0 mg/kg (R,S)-ketamine, 
producing only vehicle-appropriate responding. 
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Figure 7. The (R,S)-ketamine generalization dose effect curve for C57BL/6 mice trained to 
discriminate 5.0 mg/kg (R,S)-ketamine from vehicle (n = 12). The dashed line at 80% indicates 
the threshold to meet full generalization criteria, mean responses above this line are considered 
full generalization. Control test sessions (Ket CP and Veh CP) were conducted prior to testing of 
other doses and indicate that the discrimination training was successful. The left vertical axis and 
filled circles represent the percentage of drug lever responses (%DLR) on the (R,S)-ketamine-
paired lever. The right vertical axis and open circles represent response rate, or responses per 
minute (RPM). The figure shows mean percent drug lever responding (± SEM) and mean 
responses per minute (± SEM) for (R,S)-ketamine. Significantly different from vehicle, * = p < 
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Figure 8. (R)-ketamine generalization curve. The figure shows mean percent drug lever 
responding (± SEM) and mean responses per minute (± SEM) for (R)-ketamine (n = 6). See 
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Figure 9. (S)-ketamine generalization curve. The figure shows mean percent drug lever 
responding (± SEM) and mean responses per minute (± SEM) for (S)-ketamine (n = 7). See 
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Figure 10. (2R,6R)-hydroxynorketamine generalization curve. The figure shows mean percent 
drug lever responding (± SEM) and mean responses per minute (± SEM) for (2R,6R)-
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Figure 11. (2R,6R)-hydroxynorketamine generalization curve. The figure shows mean percent 
drug lever responding (± SEM) and mean responses per minute (± SEM) for (2R,6R)-
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Experiment 3: Spontaneous alternation in the Y-maze 
Figure 12 shows the effects of (R,S)-ketamine treatment on mean % alternation in the Y-
maze. One-way ANOVA indicated that subjects treated with (R,S)-ketamine had a significantly 
lower % alternation in the Y-maze when compared to vehicle (F (2, 33) = 4.58, p = 0.018). A 
Dunnett’s multiple comparisons test indicated that spontaneous alternation in the Y-maze was 
significantly lower when subjects were treated with 32.0 mg/kg (R,S)-ketamine (p = 0.033), but 
not 10.0 mg/kg (R,S)-ketamine (p = 0.959). One-way ANOVA indicated (R)-ketamine (Figure 
13), at the tested doses, did not produce any significant changes in % spontaneous alternation (F 
(2, 33) = 1.48, p = 0.24). One-way ANOVA indicated treatment with (S)-ketamine (Figure 14) 
significantly reduced % alternation in a Y-maze when compared to vehicle (2, 33) = 7.34, p = 
0.002. A Dunnett’s multiple comparisons test indicated that 32.0 mg/kg (S)-ketamine, but not 
16.0 mg/kg (S)-ketamine, produced a significant decrease as compared to vehicle (p = 0.036). 
One-way ANOVA (2R,6R)-hydroxynorketamine (Figure 15), at the tested doses, did not produce 
any significant changes in % spontaneous alternation (F (3, 44) = 0.84, p = 0.48) 
EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 55 
 
Figure 12. Effects of (R,S)-ketamine treatment on mean % alternation in Y-maze (n = 12 per 
group). All data are expressed as means + standard error of the mean (+SEM). The alpha level 
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Figure 13. Effects of (R)-ketamine treatment on mean % alternation in Y-maze (n = 12 per 










































EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 57 
 
Figure 14. Effects of (S)-ketamine treatment on mean % alternation in Y-maze (n = 12 per 









































EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 58 
 
Figure 15. Effects of (2R,6R)-hydroxynorketamine treatment on mean % alternation in Y-maze 
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Discussion 
 The present study tested (R,S)-ketamine, the isomers (R)-ketamine and (S)-ketamine, and 
the metabolite (2R,6R)-hydroxynorketamine in C57bl/6 mice in three preclinical behavioral 
assays; DRL task, drug discrimination, and spontaneous alternation in a Y-maze. These assays 
provided a screen for antidepressant-like effects, discriminative stimulus effects (subjective 
effects), and spatial memory (cognitive effects), respectively. In the DRL task, it was 
hypothesized that each drug, (R,S)-ketamine, (R)-ketamine, (S)-ketamine, and (2R,6R)-
hydroxynorketamine, would produce antidepressant-like effects. In the two-lever drug 
discrimination task, C57BL/6 mice were hypothesized to discriminate between 5.0 mg/kg (R,S)-
ketamine and saline. Also, it was hypothesized that the isomers (R)-ketamine and (S)-ketamine, 
but not the (2R,6R)-hydroxynorketamine metabolite would share discriminative stimulus 
properties with (R,S)-ketamine (i.e. (2R,6R)-hydroxynorketamine would not substitute for (R,S)-
ketamine). Finally, in the spontaneous alternation Y-maze assay, the mice were hypothesized to 
exhibit reduced spontaneous alternation when tested with (R,S)-ketamine and the isomer (S)-
ketamine, but not when treated with the isomer (R)-ketamine or the metabolite (2R,6R)-
hydroxynorketamine. Table 2 shows a summary of the results from each of these studies, which 
will be fully discussed in the sections below. 
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Table 2. Summary of results 
TREATMENT AIM 1: DRL AIM 2: DRUG 
DISCRIMINATION 
AIM 3: Y-MAZE 
(R,S)-KETAMINE Significant 
antidepressant-like 
effect (32.0 mg/kg) 
Full substitution Significantly reduced 
spontaneous alternation (32.0 
mg/kg) 
(R)-KETAMINE No effect at the tested 
doses 
Full substitution No effect at the tested doses 
(S)-KETAMINE Significant 
antidepressant-like 
effect (17.8 mg/kg 
and 32.0 mg/kg) 
Full substitution Significantly reduced 







No substitution No effect at the tested doses 
Note. DRL = Differential-reinforcement-of-low-rate. Significant antidepressant-like effect = significant increases in mean reinforcers 
and a significant decrease in mean responses. Full substitution = 80% or greater responding on the (R,S)-ketamine lever 
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Differential-reinforcement-of-low-rate (DRL) task 
 The DRL task is a preclinical in vivo assay for screening novel compounds to determine 
possible antidepressant-like therapeutic effects in humans. As expected, the DRL task results 
with (R,S)-ketamine in the present study with C57BL/6 mice confirmed the antidepressant-like 
effects of (R,S)-ketamine seen with other preclinical assays (FST and TST) in both mice and rats 
(Ma et al., 2013; Wang et al., 2015). One important difference in the present study’s results is 
that the antidepressant-like effects of (R,S)-ketamine were not evident until a higher dose of 32 
mg/kg was tested (see Figure 3) which is unlike other studies. For example, at least seven studies 
have demonstrated significant antidepressant-like effects with (R, S)-ketamine at 10.0 mg/kg in 
the FST and TST (Ma et al., 2013; Zhang et al., 2015; Dong et al., 2017; Fukumoto et al., 2017; 
Yamaguchi et al., 2018; Yang et al., 2018; Xiong et al., 2019). The task itself might be a factor; 
the length of the DRL test sessions are much longer than for the FST and TST. The present study 
used a 60-minute test DRL session; whereas, FST and TST are very short (usually between 5 -15 
minutes), that difference between the assays that might have influenced the results. Furthermore, 
the present study used a 72 second inter-response interval. Perhaps a DRL task with a lower 
inter-response interval (e.g. 36 seconds) would be more sensitive to drugs with antidepressant-
like effects. Contradictory results may be due to intrinsic differences in antidepressant screening 
assays and future studies should compare different methodologies. 
The hypothesis that (R)-ketamine would increase reinforcers and decrease responses in 
the DRL task (i.e., cause an antidepressant-like effect) was based on other studies that have 
reported significant antidepressant-like effects with (R)-ketamine at 10.0 mg/kg in the FST and 
TST (Yamaguchi et al., 2018; Xiong et al., 2019). However, no antidepressant-like profile was 
observed for (R)-ketamine in the present study as no significant changes in the number of 
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reinforcers or responses were observed at the tested doses (10.0 mg/kg, 17.8 mg/kg, and 32.0 
mg/kg). The present study, however, did demonstrate a significant antidepressant-like effect with 
(S)-ketamine treatment 10 minutes before the DRL task. A significant effect with (S)-ketamine 
and a non-significant effect with (R)-ketamine could be due to stereoselective differences in 
metabolism and elimination. The ketamine isomers are metabolized in a stereoselective manner; 
the demethylation of (S)-ketamine occurs more rapidly than for (R)-ketamine (Portmann et al., 
2010). Furthermore, systemic clearance of (S)-ketamine occurs more rapidly than (R)-ketamine 
(Ihmsen et al., 2001). Metabolism is critical for antidepressant-like effects because blocking the 
metabolization of ketamine has been shown to block its antidepressant-like effects (Zanos et al., 
2016). Therefore, if our DRL task was conducted with a longer pretreatment time (after (R)-
ketamine has been metabolized), then perhaps significant antidepressant-like effects in the DRL 
task with (R)-ketamine treatment would be observed. However, other studies have indicated (R)-
ketamine alone to be effective at 30-minute and 24-hour pretreatment times in the FST, which 
has a shorter test session than the hour-long DRL task (Yang et al., 2016; Yamaguchi et al., 
2018). Another possibility is that higher doses of (R)-ketamine are required to produce 
antidepressant-like effects in the DRL task. The present study observed a similar phenomenon 
with (R,S)-ketamine in the DRL task, as several studies have reported 10.0 mg/kg (R,S)-ketamine 
to be effective in mice in the FST and TST (Ma et al., 2013; Zhang et al., 2015; Dong et al., 
2017; Fukumoto et al., 2017; Yamaguchi et al., 2018; Yang et al., 2018; Xiong et al., 2019). 
While, the present study found no significant effects at 10.0 mg/kg (R,S)-ketamine, there was a 
significant effect at 32.0 mg/kg (R,S)-ketamine. Nonetheless, (R)-ketamine is of great interest 
and future studies should expand on the methodology used in the present study. 
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(2R,6R)-Hydroxynorketamine was hypothesized to increase reinforcers and reduce 
responses in the present study. Results support this hypothesis as (2R,6R)-hydroxynorketamine 
was found to produce an antidepressant-like profile in the DRL task. Other studies are in dispute 
as to whether (2R,6R)-hydroxynorketamine has antidepressant-like effects; Zanos et al. (2016) 
reported significant antidepressant-like effects; whereas, Yamaguchi et al. (2018) and Xiong et 
al. (2019) observed no effect. Furthermore, the methodology used in these studies to test 
(2R,6R)-hydroxynorketamine differed. Zanos et al. (2016) demonstrated antidepressant-like 
effects in both male and female mice using the FST and did not pre-expose mice to a chronic 
stress regimen. Yamaguchi et al. (2018) and Xiong et al. (2019) used only male mice but used 
FST and TST and did pre-expose the mice to a chronic stress regimen. Drawing definitive 
conclusions regarding antidepressant efficacy with (2R,6R)-hydroxynorketamine is limited by 
heterogeneous methodologies and findings across different studies. 
One major concern is that FST and TST are acute stressors. Testing antidepressant drugs 
in mice exposed to only an acute stressor (FST or TST) may not accurately reflect human 
depression because human depression is often associated with chronic stress (Cryan et al., 2005). 
A social defeat stress model (repeated exposure to an aggressive mouse) may overcome 
limitations associated with exposure to an acute stressor (Dong et al., 2017; Xiong et al., 2019; 
Zhang et al., 2015). Another approach for inducing stress is to pre-expose subjects to compounds 
that have been shown to increase stress, and in two studies that examined the antidepressant-like 
effects of (R,S)-ketamine, two different approaches were used. Fukumoto et al. (2017) 
administered corticosterone (20 mg/kg) daily for twenty-one days before the FST. and 
Yamaguchi et al. (2018) and Yang et al. (2018) administered a single injection of 
lipopolysaccharide (0.5 mg/kg) one day before testing (R,S)-ketamine and (2R,6R)-
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hydroxynorketamine. Both compounds, corticosterone and lipopolysaccharide, disrupt activity in 
the hypothalamic-pituitary-adrenal axis (Vakharia & Hinson, 2005), similarly to changes 
associated with human depressive symptoms and outcomes in preclinical studies (Demuyser et 
al., 2016; Keller et al., 2017). The choices made by researchers on whether to expose subjects to 
chronic stress may impact dependent variables in these preclinical studies  (such as immobility in 
the FST and TST), and future studies should consider the implications of pre-exposure to stress. 
Operant behavior in the DRL task can be impacted by stressful stimuli (Louis et al., 
2006). For example, thermal stress has been reported to significantly reduce responses and 
reduce reinforcers in the DRL task (Louis et al., 2006). Louis et al. (2006) demonstrated these 
effects when the ambient air temperature was increased to 28°C and 35°C during a DRL task 
with rats. Furthermore, exposure to thermal stress significantly increased the protein levels of 
dopamine transporters and D1 receptors in the dorsal hippocampus (a brain region implicated in 
human depressive symptoms). Dopaminergic neurons and the hippocampus play an important 
role in stress (Grace, 2012). Indeed, lesioning the hippocampus has been demonstrated to impair 
performance in a DRL task (Rawlins et al., 1983). Taken together, stress and the neurological 
underpinnings of stress have been shown to be important for the performance in the DRL task. It 
remains to be determined whether stressful stimuli also would impact the effects of (R,S)-
ketamine, its isomers, or metabolites in the DRL task. 
In the DRL task, it was hypothesized that each drug, (R,S)-ketamine, (R)-ketamine, (S)-
ketamine, and (2R,6R)-hydroxynorketamine, would produce antidepressant-like effects. It was 
found that 32.0 mg/kg (R,S)-ketamine, 17.8 mg/kg and 32.0 mg/kg (S)-ketamine, and 56.0 mg/kg 
(2R,6R)-hydroxynorketamine produced an antidepressant-like effect in DRL task. Due to the 
lack of in-house capability to synthesize a larger supply of (2R,6R)-hydroxynorketamine, and to 
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ensure enough drug was available to test in the other assays, we chose to test a single dose in the 
DRL task. This dose was chosen based on results from a study by Zanos et al. (2016) reported 
decreased immobility in the FST with (2R,6R)-hydroxynorketamine with doses ranging from 5.0 
to 125 mg/kg. A dose somewhat in the middle of this range was selected as we wanted to avoid 
doses too high that might produce undesired side effects on operant responding in the DRL task; 
however, future studies need to test a full dose-response curve with lower and higher doses. 
Furthermore, results in the present study indicated that (R)-ketamine, at the tested doses (10.0 
mg/kg, 17.8 mg/kg, and 32.0 mg/kg), produced no significant effect. The lack of effect with (R)-
ketamine treatment may be due to slower metabolism of (R)-ketamine than (S)-ketamine 
(Portmann et al., 2010). Future studies need to test higher doses of the ketamine isomers and 
longer pretreatment times in the DRL task. 
Drug Discrimination 
The present study demonstrated that (R,S)-ketamine at a dose of 5.0 mg/kg was readily 
acquired as a discriminative stimulus in C57BL/6 mice in a mean of 19.6 sessions with full 
generalization at the training dose of 5.0 mg/kg and at the 2.5 and 10.0 mg/kg doses (see Figure 
6). While the present study is the first to use 5.0 mg/kg (R,S)-ketamine as a training dose in mice, 
these results confirm other studies with both rats and mice that (R,S)-ketamine can be a salient 
discriminative stimulus (Benvenga et al., 1991; Zanos et al., 2016). Both (R)-ketamine and (S)-
ketamine shared discriminative stimulus properties with 5.0 mg/kg (R,S)-ketamine. As expected, 
the more potent (S)-ketamine isomer (Zanos et al., 2018) displayed a leftward shift (2-fold) in the 
dose-response curve as compared to (R,S)-ketamine and (R)-ketamine (see ED50 values in Table 
3). The results from testing with the ketamine isomers in the present study are novel in that no 
previous study used mice.  
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Table 3. Comparison of drugs tested in 5.0 mg/kg (R,S)-ketamine drug discrimination 
TREATMENT ED50 (+ 95% C. I.) LOWEST DOSE > 80% DRL 
(R,S)-KETAMINE 2.03 mg/kg (1.71-2.41 mg/kg) 2.5 mg/kg 
(R)-KETAMINE 2.69 mg/kg (1.43-5.05 mg/kg) 10.0 mg/kg 
(S)-KETAMINE 1.07 mg/kg (0.69-1.63 mg/kg)* 2.5 mg/kg 
(2R,6R)-HYDROXYNORKETAMINE (10 MIN) N/A ------------ 
(2R,6R)-HYDROXYNORKETAMINE (60 MIN) N/A ------------ 
Note. * Significantly different from (R,S)-ketamine, p < 0.05. C.I. = Confidence Interval. DRL = Differential-reinforcement-of-low-
rate 
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The present results also are consistent with previous findings comparing the ketamine 
isomers. Brady and Balster (1982) trained rats to discriminate phencyclidine (PCP; an 
arylcyclohexylamine like ketamine) from saline and reported that (S)-ketamine substituted at a 
lower dose than did (R)-ketamine, as it did in the present study. The differences in the effective 
doses between the ketamine isomers may be due to the same reasons listed above for the DRL 
task (differences in pharmacokinetics) along with differences in binding affinity and 
pharmacological targets (see Zanos et al. 2018). To the extent that abuse liability may be 
associated with the subjective effects of (R,S)-ketamine, (R)-ketamine may have less potential for 
abuse liability than (S)-ketamine. This finding is especially critical because (S)-ketamine was 
recently approved and is currently used to treat patients diagnosed with depression. Other 
preclinical drug discrimination studies support this concern (Shannon, 1981; Young et al., 1981). 
Shannon (1981) trained rats to discriminate between 3.0 mg/kg PCP and saline and reported that 
ketamine and other PCP analogs, which have been identified in illicit street samples, shared 
discriminative stimulus properties with PCP. As Shannon (1981) summaries at the end of the 
article, “....to the extent to which discriminative stimuli in animals are predictive of subjective 
effects in man, these results suggest that several PCP analogs may have an abuse liability similar 
to that of PCP”. Ketamine-like abuse liability and other side-effects provide a strong impetus to 
further investigate other molecules in hope of safer treatment options.  
At the tested doses, 10.0 mg/kg and 56.0 mg/kg, (2R,6R)-hydroxynorketamine failed to 
substitute for 5.0 mg/kg (R,S)-ketamine. Neither dose of (2R,6R)-hydroxynorketamine 
substituted at either 10- or 60-minute pretreatment times. These results are similar to other 
studies. Zanos et al. (2016) reported that 10.0 mg/kg and 50.0 mg/kg (2R,6R)-
hydroxynorketamine failed to substitute for a 10.0 mg/kg training dose of (R,S)-ketamine in 
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mice. The present study used a lower training dose than Zanos et al. (2016) because training dose 
has been demonstrated to be an important determining factor of the properties of discriminative 
stimuli (see Stolerman et al. 2011). The results in the present study, with a lower training dose, 
supports the conclusions drawn by Zanos et al. (2016). Namely, that (2R,6R)-
hydroxynorketamine does not appear to share subjective effects with (R,S)-ketamine. The 
clinical relevance of these findings is that (2R,6R)-hydroxynorketamine may lack the subjective 
effects that play a role in human abuse of (R,S)-ketamine. Taken together, the drug 
discrimination experiment in the present study supports the notion that (2R,6R)-
hydroxynorketamine does not appear to share discriminative stimulus properties or subjective 
effects with (R,S)-ketamine, and that it may have reduced abuse liability and reduced 
psychotomimetic effects in humans.  
Y-Maze 
 Spontaneous alternation behavior was defined as entry into all three arms of the Y-maze 
in three consecutive arm entries. Both (R,S)-ketamine 32.0 mg/kg (see Figure 12; 46.43%) and 
the isomer (S)-ketamine 32.0 mg/kg (see Figure 14; 45.60%) produced a significant reduction in 
spontaneous alternation when compared to vehicle (see Figure 12; 57.44%), thus demonstrating 
their ability to impair spatial memory cognition. In contrast, the (R)-ketamine isomer and the 
HNK metabolite did not produce any changes in spontaneous alternation at the doses tested, 
suggesting reduced impact on cognitive functioning. To date, no other studies have reported on 
the effects of (2R,6R)-hydroxynorketamine in any measure of cognition. 
Regarding the isomers of ketamine, the present study is consistent with other preclinical 
studies in that (R,S)-ketamine and (S)-ketamine leads to cognitive impairment (Garfield et al., 
1985; Hou et al., 2013). For example, Garfield et al. (1985) reported that (R,S)-ketamine and (S)-
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ketamine, but not (R)-ketamine, produced significant deficits in cognition; the maze-running 
procedure required twice-daily training for three weeks to traverse a maze for reinforcement. 
lower doses. Garfield et al. (1985) used Swiss-Webster mice and demonstrated that 15.0 mg/kg 
(R,S)-ketamine and 15.0 mg/kg (S)-ketamine produced cognitive deficits in a maze-running 
procedure. The present study, however, reported these effects at different doses. Likewise, Hou 
et al. (2013) reported 100 mg/kg (R,S)-ketamine treatment, not 25 mg/kg nor 50 mg/kg, 
decreased spontaneous alternation behavior; a much higher dose than the present study (32.0 
mg/kg). Several methodological differences may explain the difference in outcomes related to 
dose. Treatment was administered subcutaneously in the present study (which would bypass 
first-pass metabolism); whereas, Hou et al. (2013) administered (R,S)-ketamine via 
intraperitoneal injection. Furthermore, Hou et al. (2013) assessed spontaneous alternation 30-
minutes after (R,S)-ketamine treatment. The present study measured behavior after 24 hours. 
Species differences may also impact sensitivity to drug effects; the present study used C57Bl/6 
mice and Hou et al. (2013) used Swiss-Kunming mice. Control conditions also differed; the 
control group mean spontaneous alternation behavior in the present study was calculated to be 
57.44% and Hou et al. (2003) reported a mean greater than 60%. These methodological 
differences highlight the need for further replication and examination of (R,S)-ketamine-like 
side-effects. 
Limitations 
The present study had several limitations that should be addressed in future studies. A 
significant antidepressant-like effect with (R)-ketamine, in the DRL task, may be revealed by 
testing higher doses than what was tested in the present study. Based on other studies, (R)-
ketamine does have antidepressant-like effects at these tested doses in other preclinical assays 
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(i.e., FST and TST). A longer pretreatment time also may have revealed significant 
antidepressant-like effects in the DRL task, as (R)-ketamine is metabolized more slowly than (S)-
ketamine and the ketamine metabolites have been reported to play an important role in the 
antidepressant-like effects of (R,S)-ketamine (Portmann et al., 2010; Zanos et al., 2016). In 
addition, the present study used a 72 second inter-response interval in the DRL task. Perhaps a 
shorter inter-response interval time (e.g. 36 second) might reveal different (i.e. significant) 
results for (R)-ketamine. The mean number of reinforcers during the vehicle condition was very 
low in the present study, lower than that normally seen with rats on a DRL 72s schedule (see 
Hillhouse and Porter, 2014). Future studies should examine the effect of inter-response interval 
time to determine if different results would be obtained with (R)-ketamine. Testing a single dose 
of (2R,6R)-hydroxynorketamine (56.0 mg/kg) in the DRL task (which did produce an 
antidepressant-like profile) is another limitation to the current study. The choice to test a single 
dose of (2R,6R)-hydroxynorketamine in the DRL task was predicated on results reported in the 
study by Zanos et al. (2016). Zanos et al. (2016) reported (2R,6R)-hydroxynorketamine to reduce 
immobility in the FST (an antidepressant-like effect) at 5.0 mg/kg, 25.0 mg/kg, 75.0 mg/kg, and 
125 mg/kg. Given these findings, the chosen dose (56.0 mg/kg) in the present study somewhat in 
the middle of this range was hypothesized to produce an antidepressant-like effect. Future studies 
could expand on the present results by testing a full dose-response curve for (2R,6R)-
hydroxynorketamine and also including other ketamine metabolites like (2S,6S)-
hydroxynorketamine. Likewise, it is possible that higher doses of (R)-ketamine and (2R,6R)-
hydroxynorketamine may cause significant reductions in % spontaneous alternation in the Y-
maze. The present study also would be strengthened by the addition of other cognitive tasks, like 
the Morris water maze, delayed set-shifting, or delayed alternation, as all of which measure 
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different aspects of cognitive functioning. In addition, these tasks involve conditioned behavior, 
which may yield different results, as conditioned behavioral tasks have been demonstrated to be 
more sensitive to drug effects than unconditioned behavior (Louis et al., 2006). 
Conclusions 
In conclusion, the present study demonstrated that (R,S)-ketamine, (S)-ketamine, and 
(2R,6R)-hydroxynorketamine produced significant antidepressant-like effects in the DRL task, 
indicating potential treatment options for depression. The significant antidepressant-like effect in 
the DRL task observed with (2R,6R)-hydroxynorketamine treatment supports previous reports of 
antidepressant-like effects (in the FST and TST) in an assay never before used to test (2R,6R)-
hydroxynorketamine. Notably, no significant effect was observed with (R)-ketamine in the DRL 
task. This lack of effect in the DRL task may be due to the slower metabolism of (R)-ketamine as 
compared to (S)-ketamine, or differences in doses, species, or methodologies used in the present 
study. Future studies should vary the pretreatment times and testing higher doses of (R)-ketamine 
in the DRL task. The present study found (R)-ketamine to have no effect on mice in the DRL 
task, however, the promising findings reported by other studies (Shirayama & Hashimoto, 2017; 
Leal et al., 2020) provide impetus to further examine (R)-ketamine. 
In the drug discrimination experiment both isomers substituted for (R,S)-ketamine, but 
(S)-ketamine was more potent than (R)-ketamine as the ED value was shifted more than 2-fold to 
the left. Moreover, (2R,6R)-hydroxynorketamine did not substitute for (R,S)-ketamine at the 
tested doses. Results in the drug discrimination experiment support other studies, which reported 
that (2R,6R)-hydroxynorketamine did not substitute for (R,S)-ketamine at the tested doses and 
(S)-ketamine substitutes at lower doses than (R)-ketamine. Given (R,S)-ketamine is abused, and 
subjective effects play a role in abuse liability, these results indicate that (R)-ketamine and 
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(2R,2R)-hydroxynorketamine may have reduced ketamine-like abuse liability in humans, and 
they may lack other ketamine-like psychotomimetic effects. The results from the Y-maze 
experiment indicate (R)-ketamine and (2R,6R)-hydroxynorketamine may have less of an effect 
on cognition than (R,S)-ketamine and (S)-ketamine. (R,S)-Ketamine and (S)-ketamine reduced 
spontaneous alternation 24-hours after injection; whereas, no effects on spontaneous alternation 
were observed with (R)-ketamine and (2R,6R)-hydroxynorketamine at the tested doses.  
The present study reported novel findings regarding the antidepressant-like effects, 
subjective effects, and cognitive effects of (R,S)-ketamine, its isomers, and the metabolite 
(2R,6R)-hydroxynorketamine. Beyond replication and modification of methodology used in the 
present study, future studies should utilize optogenetic-mediated stimulation in combination with 
patch clamp electrophysiology to examine drug effects in relevant brain slices. Relevant brain 
regions may include the hippocampus and medial prefrontal cortex; which have been implicated 
in schizophrenia-like behavior, memory, and cognition (Kesner et al,. 2008; Yassa et al., 2011; 
Holden et al., 2012). These future studies will lead to a better understanding of the 
neurophysiological effects of novel antidepressant treatments. Moreover, completion of these 
studies will lead to greater understanding and a mechanistic insight into neuropsychiatric 
disorders associated with aberrant network activity, such as schizophrenia and depression. 
Finally, the results of the present study and many other preclinical studies suggest that clinical 
research is warranted for the (R)-ketamine (arketamine) isomer and the ketamine metabolite, 
(2R,6R)-hydroxynorketamine. 
EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 73 
References 
American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders 
(DSM-5®). American Psychiatric Pub. 
Anisman, H., & Zacharko, R. M. (1990). Multiple neurochemical and behavioral consequences of 
stressors: Implications for depression. Pharmacology & Therapeutics, 46(1), 119–136. 
https://doi.org/10.1016/0163-7258(90)90039-5 
Bandelow, B., Reitt, M., Röver, C., Michaelis, S., Görlich, Y., & Wedekind, D. (2015). Efficacy of 
treatments for anxiety disorders: A meta-analysis. International Clinical Psychopharmacology, 
30(4), 183–192. https://doi.org/10.1097/YIC.0000000000000078 
Benvenga, M. J., Wing, A. V., & Del Vecchio, R. A. (1991). The discriminative stimulus effect of 
MK-801 in ketamine-trained rats. Pharmacology, Biochemistry, and Behavior, 38(1), 211–213. 
https://doi.org/10.1016/0091-3057(91)90613-7 
Brady, K. T., & Balster, R. L. (1982). Discriminative stimulus properties of ketamine stereoisomers in 
phencyclidine-trained rats. Pharmacology Biochemistry and Behavior, 17(2), 291–295. 
https://doi.org/10.1016/0091-3057(82)90083-1 
Brody, D. J. (2018). Prevalence of Depression Among Adults Aged 20 and Over: United States, 2013–
2016. 303, 8. 
Calev, A., Cohen, R., Tubi, N., Nigal, D., Shapira, B., Kugelmass, S., & Lerer, B. (1991). 
Disorientation and Bilateral Moderately Suprathreshold Titrated ECT. Convulsive Therapy, 7(2), 
99–110. 
Carey, L. M., Rice, R. J., & Prus, A. J. (2017). The Neurotensin NTS1 Receptor Agonist PD149163 
Produces Antidepressant-Like Effects in the Forced Swim Test: Further Support for Neurotensin 
EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 74 
as a Novel Pharmacologic Strategy for Antidepressant Drugs. Drug Development Research, 
78(5), 196–202. https://doi.org/10.1002/ddr.21393 
Chen, S.-F., Chuang, C.-Y., Chao, C.-C., Yang, Y.-H., Chu, C.-Y., Yao, C.-Y., Su, Y.-C., Huang, Y.-
H., & Liao, R.-M. (2019). Task-Dependent Differences in Operant Behaviors of Rats with Acute 
Exposure to High Ambient Temperature: A Potential Role of Hippocampal Dopamine Reuptake 
Transporters. Frontiers in Behavioral Neuroscience, 13. 
https://doi.org/10.3389/fnbeh.2019.00015 
Citri, A., & Malenka, R. C. (2008). Synaptic plasticity: Multiple forms, functions, and mechanisms. 
Neuropsychopharmacology: Official Publication of the American College of 
Neuropsychopharmacology, 33(1), 18–41. https://doi.org/10.1038/sj.npp.1301559 
Cryan, J. F., Mombereau, C., & Vassout, A. (2005). The tail suspension test as a model for assessing 
antidepressant activity: Review of pharmacological and genetic studies in mice. Neuroscience 
and Biobehavioral Reviews, 29(4–5), 571–625. https://doi.org/10.1016/j.neubiorev.2005.03.009 
Dierckx, B., Heijnen, W. T., Broek, W. W. van den, & Birkenhäger, T. K. (2012). Efficacy of 
electroconvulsive therapy in bipolar versus unipolar major depression: A meta-analysis. Bipolar 
Disorders, 14(2), 146–150. https://doi.org/10.1111/j.1399-5618.2012.00997.x 
Dong, C., Zhang, J.-C., Yao, W., Ren, Q., Ma, M., Yang, C., Chaki, S., & Hashimoto, K. (2017). 
Rapid and Sustained Antidepressant Action of the mGlu2/3 Receptor Antagonist MGS0039 in 
the Social Defeat Stress Model: Comparison with Ketamine. The International Journal of 
Neuropsychopharmacology, 20(3), 228–236. https://doi.org/10.1093/ijnp/pyw089 
Drevets, W. C., Price, J. L., & Furey, M. L. (2008). Brain structural and functional abnormalities in 
mood disorders: Implications for neurocircuitry models of depression. Brain Structure & 
Function, 213(1–2), 93–118. https://doi.org/10.1007/s00429-008-0189-x 
EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 75 
Duan, T.-T., Tan, J.-W., Yuan, Q., Cao, J., Zhou, Q.-X., & Xu, L. (2013). Acute ketamine induces 
hippocampal synaptic depression and spatial memory impairment through dopamine D1/D5 
receptors. Psychopharmacology, 228(3), 451–461. https://doi.org/10.1007/s00213-013-3048-2 
Duman, C. H., & Duman, R. S. (2015). Spine synapse remodeling in the pathophysiology and 
treatment of depression. Neuroscience Letters, 601, 20–29. 
https://doi.org/10.1016/j.neulet.2015.01.022 
Duman, R. S., Malberg, J., & Thome, J. (1999). Neural plasticity to stress and antidepressant 
treatment. Biological Psychiatry, 46(9), 1181–1191. https://doi.org/10.1016/s0006-
3223(99)00177-8 
Duman, Ronald S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016). Synaptic plasticity and 
depression: New insights from stress and rapid-acting antidepressants. Nature Medicine, 22(3), 
238–249. https://doi.org/10.1038/nm.4050 
Fava, M., & Davidson, K. G. (1996). DEFINITION AND EPIDEMIOLOGY OF TREATMENT-
RESISTANT DEPRESSION. Psychiatric Clinics of North America, 19(2), 179–200. 
https://doi.org/10.1016/S0193-953X(05)70283-5 
Fink, M. (2001). Convulsive therapy: A review of the first 55 years. Journal of Affective Disorders, 
63(1–3), 1–15. https://doi.org/10.1016/s0165-0327(00)00367-0 
Franceschelli, A., Sens, J., Herchick, S., Thelen, C., & Pitychoutis, P. M. (2015). Sex differences in 
the rapid and the sustained antidepressant-like effects of ketamine in stress-naïve and 
“depressed” mice exposed to chronic mild stress. Neuroscience, 290, 49–60. 
https://doi.org/10.1016/j.neuroscience.2015.01.008 
Fukumoto, K., Iijima, M., & Chaki, S. (2016). The Antidepressant Effects of an mGlu2/3 Receptor 
Antagonist and Ketamine Require AMPA Receptor Stimulation in the mPFC and Subsequent 
EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 76 
Activation of the 5-HT Neurons in the DRN. Neuropsychopharmacology: Official Publication of 
the American College of Neuropsychopharmacology, 41(4), 1046–1056. 
https://doi.org/10.1038/npp.2015.233 
Fukumoto, K., Toki, H., Iijima, M., Hashihayata, T., Yamaguchi, J.-I., Hashimoto, K., & Chaki, S. 
(2017). Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-
Ketamine. The Journal of Pharmacology and Experimental Therapeutics, 361(1), 9–16. 
https://doi.org/10.1124/jpet.116.239228 
Ganguly, K., & Poo, M. (2013). Activity-Dependent Neural Plasticity from Bench to Bedside. 
Neuron, 80(3), 729–741. https://doi.org/10.1016/j.neuron.2013.10.028 
Garfield, J. M., Rocco, J., & Naulty, J. S. (1985). Differential effects of ketamine stereoisomers on 
maze performance in the mouse. Anesthesiology, 63(6), 681–683. 
https://doi.org/10.1097/00000542-198512000-00020 
George, M. S., & Post, R. M. (2011). Daily Left Prefrontal Repetitive Transcranial Magnetic 
Stimulation for Acute Treatment of Medication-Resistant Depression. American Journal of 
Psychiatry, 168(4), 356–364. https://doi.org/10.1176/appi.ajp.2010.10060864 
Grace, A. A. (2012). Dopamine System Dysregulation by the Hippocampus: Implications for the 
Pathophysiology and Treatment of Schizophrenia. Neuropharmacology, 62(3), 1342–1348. 
https://doi.org/10.1016/j.neuropharm.2011.05.011 
Grandjean, J., Azzinnari, D., Seuwen, A., Sigrist, H., Seifritz, E., Pryce, C. R., & Rudin, M. (2016). 
Chronic psychosocial stress in mice leads to changes in brain functional connectivity and 
metabolite levels comparable to human depression. NeuroImage, 142, 544–552. 
https://doi.org/10.1016/j.neuroimage.2016.08.013 
EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 77 
Hashimoto, K., & Shirayama, Y. (2018). What Are the Causes for Discrepancies of Antidepressant 
Actions of (2R,6R)-Hydroxynorketamine? Biological Psychiatry, 84(1), e7–e8. 
https://doi.org/10.1016/j.biopsych.2017.12.007 
Hegde, A. N., Goldberg, A. L., & Schwartz, J. H. (1993). Regulatory subunits of cAMP-dependent 
protein kinases are degraded after conjugation to ubiquitin: A molecular mechanism underlying 
long-term synaptic plasticity. Proceedings of the National Academy of Sciences, 90(16), 7436–
7440. https://doi.org/10.1073/pnas.90.16.7436 
Hillhouse, T. M., & Porter, J. H. (2014). Ketamine, but not MK-801, produces antidepressant-like 
effects in rats responding on a differential-reinforcement-of-low-rate operant schedule. 
Behavioural Pharmacology, 25(1), 80–91. https://doi.org/10.1097/FBP.0000000000000014 
Hillhouse, T. M., & Porter, J. H. (2015). A brief history of the development of antidepressant drugs: 
From monoamines to glutamate. Experimental and Clinical Psychopharmacology, 23(1), 1–21. 
https://doi.org/10.1037/a0038550 
Hillhouse, T. M., Porter, J. H., & Negus, S. S. (2014). Comparison of antidepressant-like and abuse-
related effects of phencyclidine in rats. Drug Development Research, 75(8), 479–488. 
https://doi.org/10.1002/ddr.21228 
Hillhouse, T. M., Rice, R., & Porter, J. H. (2019). What role does the (2R,6R)-hydroxynorketamine 
metabolite play in the antidepressant-like and abuse-related effects of (R)-ketamine? British 
Journal of Pharmacology, 176(19), 3886–3888. https://doi.org/10.1111/bph.14785 
Holden, H. M., Hoebel, C., Loftis, K., & Gilbert, P. E. (2012). Spatial pattern separation in 
cognitively normal young and older adults. Hippocampus, 22(9), 1826–1832. 
https://doi.org/10.1002/hipo.22017 
EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 78 
Huang, E. J., & Reichardt, L. F. (2001). Neurotrophins: Roles in Neuronal Development and 
Function. Annual Review of Neuroscience, 24(1), 677–736. 
https://doi.org/10.1146/annurev.neuro.24.1.677 
Ihmsen, H., Geisslinger, G., & Schüttler, J. (2001). Stereoselective pharmacokinetics of ketamine: 
R(−)-Ketamine inhibits the elimination of S(+)-ketamine. Clinical Pharmacology & 
Therapeutics, 70(5), 431–438. https://doi.org/10.1016/S0009-9236(01)06321-4 
International Union of Pure and Applied Chemistry, McNaught, A., & Wilkinson, A. (1997). 
Compendium of chemical terminology: IUPAC recommendations (2nd ed..). Blackwell Science. 
Ionescu, D. F., & Papakostas, G. I. (2017). Experimental medication treatment approaches for 
depression. Translational Psychiatry, 7(3), e1068. https://doi.org/10.1038/tp.2017.33 
Janssen Pharmaceutical Companies. (2019). SPRAVATO (S-ketamine) [package insert]. Titusville, 
NJ. 
Janssen Research & Development, LLC. (2019). A Study to Evaluate the Efficacy, Safety, and 
Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult 
Participants With Treatment-resistant Depression—(ClinicalTrials.gov identifier (NCT number): 
NCT02418585). https://clinicaltrials.gov/ct2/show/study/NCT02418585 
Kamaya, H. M. D., & Krishna, P. R. M. D. (1987). Ketamine Addiction.  [Letter]. Anesthesiology, 
67(5), 861–862. 
Kang, H. J., Voleti, B., Hajszan, T., Rajkowska, G., Stockmeier, C. A., Licznerski, P., Lepack, A., 
Majik, M. S., Jeong, L. S., Banasr, M., Son, H., & Duman, R. S. (2012). Decreased expression of 
synapse-related genes and loss of synapses in major depressive disorder. Nature Medicine, 18(9), 
1413–1417. https://doi.org/10.1038/nm.2886 
EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 79 
Kesner, R. P., Hunsaker, M. R., & Warthen, M. W. (2008). The CA3 subregion of the hippocampus is 
critical for episodic memory processing by means of relational encoding in rats. Behavioral 
Neuroscience, 122(6), 1217–1225. https://doi.org/10.1037/a0013592 
Kessler, R. C. (2012). The costs of depression. The Psychiatric Clinics of North America, 35(1), 1–14. 
https://doi.org/10.1016/j.psc.2011.11.005 
Khanegheini, A., Meftahi, G. H., Zarrindast, M. R., Afarinesh, M. R., Sahraei, H., Jahromi, G. P., & 
Shahyad, S. (2019). Involvement of CA1 GABAA Receptors in Ketamine-Induced Impairment 
of Spatial and Non-Spatial Novelty Detection in Mice. Neurochemical Journal, 13(1), 81–89. 
https://doi.org/10.1134/S1819712419010094 
Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen, P. A., 
Yu, B., Zaslavsky, L., Zhang, J., & Bolton, E. E. (2019). PubChem 2019 update: Improved 
access to chemical data. Nucleic Acids Research, 47(Database issue), D1102–D1109. 
https://doi.org/10.1093/nar/gky1033 
Kraeuter, A.-K., Guest, P. C., & Sarnyai, Z. (2019). The Y-Maze for Assessment of Spatial Working 
and Reference Memory in Mice. Methods in Molecular Biology (Clifton, N.J.), 1916, 105–111. 
https://doi.org/10.1007/978-1-4939-8994-2_10 
Krishnan, V., & Nestler, E. J. (2011). Animal Models of Depression: Molecular Perspectives. Current 
Topics in Behavioral Neurosciences, 7, 121–147. https://doi.org/10.1007/7854_2010_108 
Kujala, I., Rosenvinge, B., & Bekkelund, S. I. (2002). Clinical Outcome and Adverse Effects of 
Electroconvulsive Therapy in Elderly Psychiatric Patients. Journal of Geriatric Psychiatry and 
Neurology, 15(2), 73–76. https://doi.org/10.1177/089198870201500204 
Kültz, D. (2005). Molecular and evolutionary basis of the cellular stress response. Annual Review of 
Physiology, 67, 225–257. https://doi.org/10.1146/annurev.physiol.67.040403.103635 
EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 80 
Liston, C., Miller, M. M., Goldwater, D. S., Radley, J. J., Rocher, A. B., Hof, P. R., Morrison, J. H., 
& McEwen, B. S. (2006). Stress-Induced Alterations in Prefrontal Cortical Dendritic 
Morphology Predict Selective Impairments in Perceptual Attentional Set-Shifting. Journal of 
Neuroscience, 26(30), 7870–7874. https://doi.org/10.1523/JNEUROSCI.1184-06.2006 
Liu, W., Ge, T., Leng, Y., Pan, Z., Fan, J., Yang, W., & Cui, R. (2017). The Role of Neural Plasticity 
in Depression: From Hippocampus to Prefrontal Cortex. Neural Plasticity, 2017, 6871089. 
https://doi.org/10.1155/2017/6871089 
Liu, Y., Lin, D., Wu, B., & Zhou, W. (2016). Ketamine abuse potential and use disorder. Brain 
Research Bulletin, 126, 68–73. https://doi.org/10.1016/j.brainresbull.2016.05.016 
Louis, C., Cohen, C., Depoortère, R., & Griebel, G. (2006). Antidepressant-Like Effects of the 
Corticotropin-Releasing Factor 1 Receptor Antagonist, SSR125543, and the Vasopressin 1b 
Receptor Antagonist, SSR149415, in a DRL-72 s Schedule in the Rat. 
Neuropsychopharmacology, 31(10), 2180–2187. https://doi.org/10.1038/sj.npp.1301036 
Ma, X.-C., Dang, Y.-H., Jia, M., Ma, R., Wang, F., Wu, J., Gao, C.-G., & Hashimoto, K. (2013). 
Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor 
SB216763, in the chronic mild stress model of mice. PloS One, 8(2), e56053. 
https://doi.org/10.1371/journal.pone.0056053 
MacGillivray, S., Arroll, B., Hatcher, S., Ogston, S., Reid, I., Sullivan, F., Williams, B., & Crombie, 
I. (2003). Efficacy and tolerability of selective serotonin reuptake inhibitors compared with 
tricyclic antidepressants in depression treated in primary care: Systematic review and meta-
analysis. BMJ (Clinical Research Ed.), 326(7397), 1014. 
https://doi.org/10.1136/bmj.326.7397.1014 
EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 81 
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008). 
Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-
hydroxy-5-methylisoxazole-4-propionic acid receptors. Biological Psychiatry, 63(4), 349–352. 
https://doi.org/10.1016/j.biopsych.2007.05.028 
Marken, P. A., & Munro, J. S. (2000). Selecting a Selective Serotonin Reuptake Inhibitor: Clinically 
Important Distinguishing Features. The Primary Care Companion for CNS Disorders, 2(6), 205–
210. https://doi.org/10.4088/PCC.v02n0602 
Miedel, C. J., Patton, J. M., Miedel, A. N., Miedel, E. S., & Levenson, J. M. (2017). Assessment of 
Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse 
Models of Amyloid-β and Tau Neuropathology. Journal of Visualized Experiments: JoVE, 123. 
https://doi.org/10.3791/55523 
Mineur, Y. S., & Picciotto, M. R. (2010). Nicotine receptors and depression: Revisiting and revising 
the cholinergic hypothesis. Trends in Pharmacological Sciences, 31(12), 580–586. 
https://doi.org/10.1016/j.tips.2010.09.004 
Moaddel, R., Sanghvi, M., Dossou, K. S. S., Ramamoorthy, A., Green, C., Bupp, J., Swezey, R., 
O’Loughlin, K., & Wainer, I. W. (2015). The distribution and clearance of (2S,6S)-
hydroxynorketamine, an active ketamine metabolite, in Wistar rats. Pharmacology Research & 
Perspectives, 3(4). https://doi.org/10.1002/prp2.157 
Moffa, A., Martin, D., Brunoni, A., Alonzo, A., Blumberger, D., Bennabi, D., Daskalakis, Z., Fregni, 
F., Padberg, F., Palm, U., Sampaio-Junior, B., & Loo, C. (2019). Transcranial direct current 
stimulation for acute major depressive episodes: An updated meta-analysis of individual patient 
data. Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation, 12(2), 
479. https://doi.org/10.1016/j.brs.2018.12.562 
EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 82 
Murray, C. J. L., & Lopez, A. D. (1996). Evidence-Based Health Policy—Lessons from the Global 
Burden of Disease Study. Science, 274(5288), 740–743. 
https://doi.org/10.1126/science.274.5288.740 
National Institute of Mental Health, (NIMH). (2016, December 1). Depression Basics. 
/nimh/nimh/product/Depression-Basics/TR 16-3561 
Ochs-Ross, R., Daly, E., Zhang, Y., Lane, R., Lim, P., Foster, K., Hough, D., Manji, H., Drevets, W., 
Sanacora, G., Adler, C., McShane, R., Gaillard, R., & Singh, J. (2019). Efficacy and safety of 
esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant 
depression. European Neuropsychopharmacology, 29, S355–S356. 
https://doi.org/10.1016/j.euroneuro.2018.11.548 
O’Donnell, J. M., Marek, G. J., & Seiden, L. S. (2005). Antidepressant effects assessed using 
behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule. 
Neuroscience and Biobehavioral Reviews, 29(4–5), 785–798. 
https://doi.org/10.1016/j.neubiorev.2005.03.018 
Papakostas, G. I. (2014). Cognitive symptoms in patients with major depressive disorder and their 
implications for clinical practice. The Journal of Clinical Psychiatry, 75(1), 8–14. 
https://doi.org/10.4088/JCP.13r08710 
Patel, S., & Holle, L. M. (2019). Spravato for Treatment-Resistant Depression. Drug Topics; 
Monmouth Junction, 163(5), 40. 
Petit-Demouliere, B., Chenu, F., & Bourin, M. (2005). Forced swimming test in mice: A review of 
antidepressant activity. Psychopharmacology, 177(3), 245–255. https://doi.org/10.1007/s00213-
004-2048-7 
EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 83 
Pham, T. H., Defaix, C., Xu, X., Deng, S.-X., Fabresse, N., Alvarez, J.-C., Landry, D. W., Brachman, 
R. A., Denny, C. A., & Gardier, A. M. (2018). Common Neurotransmission Recruited in (R,S)-
Ketamine and (2R,6R)-Hydroxynorketamine–Induced Sustained Antidepressant-like Effects. 
Biological Psychiatry, 84(1), e3–e6. https://doi.org/10.1016/j.biopsych.2017.10.020 
Philip, N. S., Carpenter, L. L., Tyrka, A. R., & Price, L. H. (2010). Nicotinic acetylcholine receptors 
and depression: A review of the preclinical and clinical literature. Psychopharmacology, 212(1), 
1–12. https://doi.org/10.1007/s00213-010-1932-6 
Popovic, D., Vieta, E., Fornaro, M., & Perugi, G. (2015). Cognitive tolerability following successful 
long term treatment of major depression and anxiety disorders with SSRI antidepressants. 
Journal of Affective Disorders, 173, 211–215. https://doi.org/10.1016/j.jad.2014.11.008 
Porsolt, R. D., Bertin, A., & Jalfre, M. (1977). Behavioral despair in mice: A primary screening test 
for antidepressants. Archives Internationales de Pharmacodynamie et de Therapie, 229(2), 327–
336. 
Porsolt, R. D., Le Pichon, M., & Jalfre, M. (1977). Depression: A new animal model sensitive to 
antidepressant treatments. Nature, 266(5604), 730–732. https://doi.org/10.1038/266730a0 
Porter, J. H., Prus, A. J., & Overton, D. A. (2018). Drug Discrimination: Historical Origins, Important 
Concepts, and Principles. Current Topics in Behavioral Neurosciences, 39, 3–26. 
https://doi.org/10.1007/7854_2018_40 
Porter, J. H., Prus, A. J., Vann, R. E., & Varvel, S. A. (2005). Discriminative stimulus properties of 
the atypical antipsychotic clozapine and the typical antipsychotic chlorpromazine in a three-
choice drug discrimination procedure in rats. Psychopharmacology, 178(1), 67–77. 
https://doi.org/10.1007/s00213-004-1985-5 
EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 84 
Portmann, S., Kwan, H. Y., Theurillat, R., Schmitz, A., Mevissen, M., & Thormann, W. (2010). 
Enantioselective capillary electrophoresis for identification and characterization of human 
cytochrome P450 enzymes which metabolize ketamine and norketamine in vitro. Journal of 
Chromatography A, 1217(51), 7942–7948. https://doi.org/10.1016/j.chroma.2010.06.028 
PubChem. (2020, February). Limonene. https://pubchem.ncbi.nlm.nih.gov/compound/22311 
Rajagopal, L., Burgdorf, J. S., Moskal, J. R., & Meltzer, H. Y. (2016). GLYX-13 (rapastinel) 
ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in 
mice. Behavioural Brain Research, 299, 105–110. https://doi.org/10.1016/j.bbr.2015.10.060 
Rawlins, J. N., Winocur, G., & Gray, J. A. (1983). The hippocampus, collateral behavior, and timing. 
Behavioral Neuroscience, 97(6), 857–872. https://doi.org/10.1037//0735-7044.97.6.857 
Roca, M., Vives, M., López-Navarro, E., García-Campayo, J., & Gili, M. (2015). Cognitive 
impairments and depression: A critical review. Actas Espanolas de Psiquiatria, 43(5), 187–193. 
Rudorfer, M. V., Henry, M. E., & Sackeim, H. A. (n.d.). Electroconvulsive Therapy. 37. 
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., 
Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., Kupfer, D. J., Rosenbaum, J. F., Alpert, J., 
Stewart, J. W., McGrath, P. J., Biggs, M. M., Shores-Wilson, K., Lebowitz, B. D., Ritz, L., … 
STAR*D Investigators Group. (2004). Sequenced treatment alternatives to relieve depression 
(STAR*D): Rationale and design. Controlled Clinical Trials, 25(1), 119–142. 
Sałat, K., Siwek, A., Starowicz, G., Librowski, T., Nowak, G., Drabik, U., Gajdosz, R., & Popik, P. 
(2015a). Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced 
swim test: Role of activity at NMDA receptor. Neuropharmacology, 99, 301–307. 
https://doi.org/10.1016/j.neuropharm.2015.07.037 
EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 85 
Sałat, K., Siwek, A., Starowicz, G., Librowski, T., Nowak, G., Drabik, U., Gajdosz, R., & Popik, P. 
(2015b). Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced 
swim test: Role of activity at NMDA receptor. Neuropharmacology, 99, 301–307. 
https://doi.org/10.1016/j.neuropharm.2015.07.037 
Sanger, D. J., & Blackman, D. E. (1989). Operant Behavior and the Effects of Centrally Acting 
Drugs. In A. A. Boulton, G. B. Baker, & A. J. Greenshaw (Eds.), Psychopharmacology (pp. 
299–348). Humana Press. https://doi.org/10.1385/0-89603-129-2:299 
Sassano‐Higgins, S., Baron, D., Juarez, G., Esmaili, N., & Gold, M. (2016). A Review of Ketamine 
Abuse and Diversion. Depression and Anxiety, 33(8), 718–727. https://doi.org/10.1002/da.22536 
Shirayama, Y., & Hashimoto, K. (2017). Lack of Antidepressant Effects of (2R,6R)-
Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine. 
International Journal of Neuropsychopharmacology, 21(1), 84–88. 
https://doi.org/10.1093/ijnp/pyx108  
Shannon HE (1981) Evaluation of PCP Analogs on the Basis of Their Discriminative Stimulus 
Properties in the rat. Journal of Pharmacology and Experimental Therapeutics. 216 (3): 543-551 
Siegel, R. K. (1978). Phencyclidine and ketamine intoxication: A study of four populations of 
recreational users. NIDA Research Monograph, 21, 119–147. 
Slattery, D. A., & Cryan, J. F. (2012). Using the rat forced swim test to assess antidepressant-like 
activity in rodents. Nature Protocols; London, 7(6), 1009–1014. 
http://dx.doi.org.proxy.library.vcu.edu/10.1038/nprot.2012.044 
Sloman, L. (2008). A new comprehensive evolutionary model of depression and anxiety. Journal of 
Affective Disorders, 106(3), 219–228. https://doi.org/10.1016/j.jad.2007.07.008 
EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 86 
Snigdha, S., Milgram, N. W., Willis, S. L., Albert, M., Weintraub, S., Fortin, N. J., & Cotman, C. W. 
(2013). A preclinical cognitive test battery to parallel the National Institute of Health Toolbox in 
humans: Bridging the translational gap. Neurobiology of Aging, 34(7), 1891–1901. 
https://doi.org/10.1016/j.neurobiolaging.2013.01.018 
Solinas, M., Panlilio, L. V., Justinova, Z., Yasar, S., & Goldberg, S. R. (2006). Using drug-
discrimination techniques to study the abuse-related effects of psychoactive drugs in rats. Nature 
Protocols, 1(3), 1194–1206. https://doi.org/10.1038/nprot.2006.167 
Steru, L., Chermat, R., Thierry, B., & Simon, P. (1985). The tail suspension test: A new method for 
screening antidepressants in mice. Psychopharmacology, 85(3), 367–370. 
https://doi.org/10.1007/bf00428203 
Stolerman, I. P., Childs, E., Ford, M. M., & Grant, K. A. (2011). The role of training dose in drug 
discrimination: A review. Behavioural Pharmacology, 22(5–6), 415–429. 
https://doi.org/10.1097/FBP.0b013e328349ab37 
Swedberg, M. (2016). Critical role for drug discrimination studies in the assessment of abuse liability 
of novel compounds. Journal of Pharmacological and Toxicological Methods, 81, 338. 
https://doi.org/10.1016/j.vascn.2016.02.011 
Thierry, B., Steru, L., Chermat, R., & Simon, P. (1984). Searching—waiting strategy: A candidate for 
an evolutionary model of depression? Behavioral and Neural Biology, 41(2), 180–189. 
https://doi.org/10.1016/S0163-1047(84)90555-7 
Thomas, C. (2018, February 18). Development of (2R,6R)-Hydroxynorketamine. National Center for 
Advancing Translational Sciences. https://ncats.nih.gov/chemtech/projects/active/ketamine 
EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 87 
Uher, R., Payne, J. L., Pavlova, B., & Perlis, R. H. (2014). Major Depressive Disorder in Dsm-5: 
Implications for Clinical Practice and Research of Changes from DSM-IV. Depression and 
Anxiety, 31(6), 459–471. https://doi.org/10.1002/da.22217 
Verma, A., & Moghaddam, B. (1996). NMDA receptor antagonists impair prefrontal cortex function 
as assessed via spatial delayed alternation performance in rats: Modulation by dopamine. Journal 
of Neuroscience, 16(1), 373–379. https://doi.org/10.1523/JNEUROSCI.16-01-00373.1996 
Wang, J. H., Fu, Y., Wilson, F. A. W., & Ma, Y. Y. (2006). Ketamine affects memory consolidation: 
Differential effects in T-maze and passive avoidance paradigms in mice. Neuroscience, 140(3), 
993–1002. https://doi.org/10.1016/j.neuroscience.2006.02.062 
Wang, N., Yu, H.-Y., Shen, X.-F., Gao, Z.-Q., Yang, C., Yang, J.-J., & Zhang, G.-F. (2015). The 
rapid antidepressant effect of ketamine in rats is associated with down-regulation of pro-
inflammatory cytokines in the hippocampus. Upsala Journal of Medical Sciences, 120(4), 241–
248. https://doi.org/10.3109/03009734.2015.1060281 
Warner‐Schmidt, J. L., & Duman, R. S. (2006). Hippocampal neurogenesis: Opposing effects of 
stress and antidepressant treatment. Hippocampus, 16(3), 239–249. 
https://doi.org/10.1002/hipo.20156 
Williams, J. W., Mulrow, C. D., Chiquette, E., Noël, P. H., Aguilar, C., & Cornell, J. (2000). A 
systematic review of newer pharmacotherapies for depression in adults: Evidence report 
summary. Annals of Internal Medicine, 132(9), 743–756. 
World Health Organization [WHO]. (n.d.). Depression. Retrieved November 15, 2019, from 
https://www.who.int/news-room/fact-sheets/detail/depression 
Xiong, Z., Fujita, Y., Zhang, K., Pu, Y., Chang, L., Ma, M., Chen, J., & Hashimoto, K. (2019). 
Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the 
EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 88 
depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic 
social defeat stress model. Behavioural Brain Research, 368, 111904. 
https://doi.org/10.1016/j.bbr.2019.111904 
Yamaguchi, J.-I., Toki, H., Qu, Y., Yang, C., Koike, H., Hashimoto, K., Mizuno-Yasuhira, A., & 
Chaki, S. (2018). (2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of 
(R)-ketamine in mice. Neuropsychopharmacology: Official Publication of the American College 
of Neuropsychopharmacology, 43(9), 1900–1907. https://doi.org/10.1038/s41386-018-0084-y 
Yang, B., Zhang, J.-C., Han, M., Yao, W., Yang, C., Ren, Q., Ma, M., Chen, Q.-X., & Hashimoto, K. 
(2016). Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat 
stress model of depression. Psychopharmacology, 233(19–20), 3647–3657. 
https://doi.org/10.1007/s00213-016-4399-2 
Yang, C., Han, M., Zhang, J., Ren, Q., & Hashimoto, K. (2016). Loss of parvalbumin-
immunoreactivity in mouse brain regions after repeated intermittent administration of 
esketamine, but not R-ketamine. Psychiatry Research, 239, 281–283. 
https://doi.org/10.1016/j.psychres.2016.03.034 
Yang, C., Kobayashi, S., Nakao, K., Dong, C., Han, M., Qu, Y., Ren, Q., Zhang, J., Ma, M., Toki, H., 
Yamaguchi, J., Chaki, S., Shirayama, Y., Nakazawa, K., Manabe, T., & Hashimoto, K. (2018). 
AMPA Receptor Activation–Independent Antidepressant Actions of Ketamine Metabolite (S)-
Norketamine. Biological Psychiatry, 84(8), 591–600. 
https://doi.org/10.1016/j.biopsych.2018.05.007 
Yang, C., Qu, Y., Abe, M., Nozawa, D., Chaki, S., & Hashimoto, K. (2017). (R)-Ketamine Shows 
Greater Potency and Longer Lasting Antidepressant Effects Than Its Metabolite (2R,6R)-
EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 89 
Hydroxynorketamine. Biological Psychiatry, 82(5), e43–e44. 
https://doi.org/10.1016/j.biopsych.2016.12.020 
Yassa, M. A., Lacy, J. W., Stark, S. M., Albert, M. S., Gallagher, M., & Stark, C. E. L. (2011). Pattern 
separation deficits associated with increased hippocampal CA3 and dentate gyrus activity in 
nondemented older adults. Hippocampus, 21(9), 968–979. https://doi.org/10.1002/hipo.20808  
Young AM, Herling S, Winger GD, Woods JH. (1981) Comparison of discriminative and reinforcing 
effects of ketamine and related compounds in the rhesus monkey. NIDA Res Monogr. 
Feb;34:173-179 
Young, R. (2009). Drug Discrimination. In J. J. Buccafusco (Ed.), Methods of Behavior Analysis in 
Neuroscience (2nd ed.). CRC Press/Taylor & Francis. 
http://www.ncbi.nlm.nih.gov/books/NBK5225/ 
Zanos, P., Highland, J. N., Stewart, B. W., Georgiou, P., Jenne, C. E., Lovett, J., Morris, P. J., 
Thomas, C. J., Moaddel, R., Zarate, C. A., & Gould, T. D. (2019). (2R,6R)-hydroxynorketamine 
exerts mGlu2 receptor-dependent antidepressant actions. Proceedings of the National Academy 
of Sciences of the United States of America, 116(13), 6441–6450. 
https://doi.org/10.1073/pnas.1819540116 
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., 
Pribut, H. J., Singh, N. S., Dossou, K. S. S., Fang, Y., Huang, X.-P., Mayo, C. L., Wainer, I. W., 
Albuquerque, E. X., Thompson, S. M., Thomas, C. J., Zarate, C. A., & Gould, T. D. (2016). 
NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature, 
533(7604), 481–486. https://doi.org/10.1038/nature17998 
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., 
Albuquerque, E. X., Thomas, C. J., Zarate, C. A., & Gould, T. D. (2018). Ketamine and 
EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 90 
Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. Pharmacological 
Reviews, 70(3), 621–660. https://doi.org/10.1124/pr.117.015198 
Zhang, J., Yao, W., Dong, C., Yang, C., Ren, Q., Ma, M., Han, M., & Hashimoto, K. (2015). 
Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social 
defeat stress model of depression. Psychopharmacology, 232(23), 4325–4335. 
https://doi.org/10.1007/s00213-015-4062-3 
  
EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 91 




Name: Remington J Rice 
Born: 21 July 1992 - Traverse City, MI 
Curriculum Vita: May 2020 
 
Main areas of research: Novel therapeutic molecules for depression, schizophrenia, 
Alzheimer/memory, machine learning algorithms for video processing behavior in 
preclinical assays, optogenetics, and calcium imaging (GCaMP6f) 
 
Remington Rice is a US American neuroscientist and adjunct faculty member at Virginia Commonwealth 
University (VCU) in Richmond, VA. He originally studied experimental psychology and biology at 
Northern Michigan University (NMU) in Marquette, MI. He is passionate about teaching and mentoring 
future scientists. 
Academic and professional career 
2016 - 2020 Ph.D. (Psychology) VCU 
since 2018 adjunct faculty instructor (Physiological psychology, PSYC 401) VCU 
2016 - 2018 Substitute teacher (Biopsychology) Maggie L. Walker Governor’s School 
2014 - 2016 M.S. (Experimental Psychology) NMU 
2014 - 2016 Research assistant NMU 
2010 - 2014 B.S. (Psychology & Biology) NMU 
Select publications 
Hillhouse, T. M., Rice, R., & Porter, J. H. (2019). What role does the (2R,6R)-
hydroxynorketamine metabolite play in the antidepressant-like and abuse-related effects 
of (R)-ketamine? British Journal of Pharmacology, 176(19), 3886–3888. 
https://doi.org/10.1111/bph.14785 
Carey, L. M., Rice, R. J., & Prus, A. J. (2017). The Neurotensin NTS1 Receptor Agonist 
PD149163 Produces Antidepressant-Like Effects in the Forced Swim Test: Further 
 
EFFECTS OF (R,S)-KETAMINE AND (2R,6R)-HYDROXYNORKETAMINE 92 
Support for Neurotensin as a Novel Pharmacologic Strategy for Antidepressant Drugs. 
Drug Development Research, 78(5), 196–202. https://doi.org/10.1002/ddr.21393 
Rice, R. (2013). Juan Huarte. In C. Pernaski, N. Fraire, E. DePetro, C. Brown, S. Wagner, H. 
Whitaker, E. Smith, T. Clark, L. Carey, M. Moore, B. Palmer, K. England and J. 
Fancher (Eds.), Approaches to a History of Western Psychology - an e-textbook. (2nd 
ed.). Published online; please contact Professor Whitaker hwhitake@nmu.edu for 
access. 
Conference presentations 
Rice, R., Zhang, F., Goswamee, P., McQuiston A., Porter, J (2019) Effects of Ketamine and (2R-6R)-
hydroxynorketamine (HNK) on Cognition: A Role for the Nucleus Reuniens? Society for Neuroscience 
Chicago Il  
Rice, R., Messer, Z., Whitehouse, S., Ottem, E., Adam Prus, A. (2016) Effects of Optogenetic Activation 
and Pharmacological Modulation of Dopaminergic Neurons. Society for Neuroscience, San Diego, CA 
Carey, L., Rice, R., Prus AJ (2014) The Neurotensin NTS1 Receptor Agonist PD149163 Exhibits Anti-
Depressant like Effects in a Forced Swim Test. Society for Neuroscience, Washington, D.C. 
Memberships in professional societies 
 Society for Neuroscience 
 European Behavioral Pharmacological Society 
 American Psychological Association 
